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A B S T R A C T 
 
The continuous production of fetal haemoglobin (HbF, α2γ2) into adulthood is an 
ameliorating factor in sickle cell disease and β-thalassemia. We have previously 
mapped two quantitative trait loci (QTLs) controlling HbF levels, one in intron 2 of 
BCL11A gene, and the other, an intergenic region on chromosome 6 between the 
genes HBS1L and MYB, known as HMIP. 
Histone modification and RNA polymerase II binding at these loci and at the globin 
genes themselves were analysed using microarray-based chromatin 
immunoprecipitation studies of primary human erythroid progenitor cells. In 
addition, we analysed binding of GATA-1 and KLF1, two major erythroid-specific 
transcription factors. 
Strong GATA-1 binding at the HMIP region coinciding with strong histone 
acetylation and RNA polymerase II activity was seen, indicative of the presence of 
regulatory elements in the intergenic region. Moreover, differential GATA-1 binding 
was observed between individuals with low HbF and raised HbF levels at a site 
within the HMIP region most strongly associated with HbF variance. 
BCL11A intron 2 also showed strong GATA-1 binding and histone H3 acetylation, 
and may therefore be responsible for the overall regulation of BCL11A. I have 
carried out extensive sequence analysis of individuals from the upper and lower 
extremes of BCL11A-associated HbF levels to fully characterize DNA variants. The 
nature of this sequence as a regulator of BCL11A expression remains to be 
determined and functional tests are on-going.  
The role of BCL11A, in conjunction with KLF1, as a transcriptional regulator of the α 
and β globin loci, as well as the QTLs themselves, was also investigated. These 
results show that BCL11A, often alongside GATA-1, is intimately involved in the 
transcriptional regulation of the globin genes and that KLF1 also regulates BCL11A. 
The importance of different protein isoforms of BCL11A is also explored. 
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      C H A P T E R  1 





In 1840, Liepzig, Germany, a crystalline substance was discovered in earthworms 
which was later identified as haemoglobin. Haemoglobin is the protein that carries 
oxygen in red blood cells (erythrocytes) and delivers it to all body tissues where it is 
exchanged with carbon dioxide and later expelled via the lungs.  
The molecular structure of haemoglobin (Hb) was determined by Max Perutz in 
1959 using x-ray crystallography. Haemoglobin consists of two α-like globin chains 
and two β-like globin chains (Figure 1.2) with each chain containing an oxygen 
carrying heme group (Perutz et al. 1960). 
In keeping with the changing oxygen affinity demands during human development, 
different forms of the haemoglobin protein are synthesised to fulfil these 
requirements. A total of six types of haemoglobin exist, and the first three, Gower I 
(ζ2ε2), Gower II (α2ε2), and Portland (ζ2γ2) are only produced in the embryo 
(Huehns et al. 1964). The first switch occurs from embryonic to fetal haemoglobin 
(α2γ2) at about 6-8 weeks of gestation. Around birth the second switch is from fetal 
to adult haemoglobin (HbA2; α2δ2 and HbA; α2β2). HbA2 is a minor form of 
haemoglobin which makes up 2-3% of total haemoglobin (Kunkel & Wallenius 
1955). HbA represents more than 95% of total haemoglobin and remains the 






Figure 1.1 ß-like globin gene expression. The embryonic gene is expressed during the first six 
weeks of gestation. The first switch from ε- to γ-globin occurs shortly after conception, and the 







The genes responsible for the synthesis of Hb in humans are found in two gene 
clusters. The α-globin gene cluster at chromosome 16 contains the ζ-globin gene 
and the α-globin gene. The β-globin gene cluster is located on chromosome 11 and 
contains the ε, Gγ, Aγ,δ, and β genes (Stamatoyannopoulos 2005)(Fig. 1.5). In  both 
clusters the globin genes are arranged in the order in which they are expressed 











Figure 1.2 Schematic of the globin genes and gene products that constitute the fetal and adult 
haemoglobin molecules. 
 
1.2 Haematopoiesis & Erythropoiesis 
 
Haematopoiesis is defined as the formation of blood cells. This process takes place 
at multiple sites throughout development and can be divided into two stages: 
Primitive haematopoiesis occurs during the earliest weeks of gestation, in the 
embryonic yolk sac; definitive haematopoiesis occurs in several locations; the aorta-
gonads-mesonephros (AGM) region is the initial site of definitive haematopoiesis 
followed by the liver and spleen. From around 2 months until 6-7 months of fetal 
life, the liver and spleen are the major haematopoietic organs, after which, the 
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bone marrow begins to take over the task and eventually becomes the exclusive 
site of haematopoiesis throughout childhood and adult life (Dzierzak 2005)(Fig. 1.3). 
 
 
Figure 1.3 Sites of haematopoiesis during human development. (Image adapted from 
M.Komorniczak, 2011) 
 
All blood cells are derived from a common pluripotent haematopoietic stem cell 
(HSC) and differentiation begins after they are committed to either the myeloid or 
lymphoid lineage, as a myeloid progenitor cell or lymphoid progenitor cell, 
respectively. 
Erythrocytes (red blood cells) are derived from the myeloid progenitor cells. The 
earliest forms of myeloid progenitor cells are burst forming units-erythroid (BFU-e). 
BFU-e develop into colony forming units-erythroid (CFU-e). These progenitor cells 
develop into precursor cells and become erythropoietin responsive. These 
erythropoietin responsive cells (ERC) go through several stages, proliferating and 






CFU-e develop into pro-erythroblasts, basophilic erythroblasts, polychromatic 
erythroblasts and orthochromatic erythroblasts (Fig.1.4). In the next stage of 
development these cells lose the ability to divide, followed by extrusion of the 
nucleus and loss of organelles. The cells are now referred to as reticulocytes. 
Reticulocytes are released into the blood stream where they mature into 
erythrocytes (Philipsen & Wood, 2009). 
Erythrocytes in circulation have a 120 day lifespan. Towards the end of this time 
they are cleared from the circulatory system as new reticulocytes are released and 
mature into erythrocytes. The rate by which red cell production is regulated is 
controlled by erythropoietin (EPO) levels. EPO stimulates erythropoiesis by 
increasing the rate of maturation of the ERCs into pro-erythroblasts (Philipsen & 
Wood, 2009).  
 
Figure 1.4 Human erythroid differentiation. Cells grown by the two-phase liquid culture method adapted 
from Fibach et al.  
 
Mature erythrocytes contain haemoglobin which represents more than 95% of total 
cytoplasmic protein content of the cell. 
The growth of erythroid progenitor cells is dependent on specific growth factors. 
Stem cell factor-SCF (also known as Steel factor or Kit ligand) is required for HSC to  
BFU-e stage, which express the SCF-R (Stem cell factor-Receptor) which binds SCF. 
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SCF is required to induce proliferation and differentiation of these cells (Broudy 
1997). Interleukin-3 (IL-3) is a cytokine that promotes cell survival and proliferation 
by binding to IL-3R expressed on HSCs through to early progenitor cells. The 
granuolocyte-macrophage colony stimulating factor (GM-CSF) is required again 
from HSC to BFU-e stage and promotes proliferation (Migliaccio & 
Papayannopoulou 2001). Erythropoietin (EPO) is an essential growth factor in 
erythropoiesis which is expressed slightly later than the other growth factors but 
becomes paramount for cell development. EPO drives the proliferation and 
expansion of the developing erythroid progenitors from BFU-e stage through to 
terminal differentiation to haemoglobinized cells (Philipsen & Wood 2009). 
Erythroid progenitors can thus be identified by the cell-surface expression of 
receptors for these specific growth factors. 
 
1.3 Control of the β-globin gene locus 
 
Both cis (including promoters, enhancers, silencers and insulators) and trans-acting 
elements are involved in the expression of the β-globin like genes. 
Globin gene promoters have sequences in common at specific distances from the 
transcriptional start site (TSS). The TATA sequence is found 30 bp upstream of the 
TSS, the CCAAT site is found 70-78 bp upstream of the TSS and the CACCC sequence 
is located 80-140 bp upstream of the TSS. The CACCC sequence is specific to 
erythroid specific gene promoters, whereas the other sequences are found in many 
eukaryotic promoters. These sequences are important in globin gene expression as 
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down regulation of the globin genes is seen when natural mutations occur at these 
sites (Forget, 2001). 
1.3.1 The β-globin Locus Control Region (LCR) 
 
The β-globin gene locus is controlled exclusively on a transcriptional level. Genes 
that have an ‘open’ chromatin structure (euchromatin) are transcriptionally active, 
whereas transcriptionally silent genes have a ‘closed’ chromatin structure 
(heterochromatin). Open chromatin is hypersensitive to nuclease digestion while 
closed chromatin is resistant to DNase I digestion. Thus, transcriptionally active 
sites can be identified by their hypersensitivity to DNase I.  
6-20kb upstream of the β-globin locus is the locus control region or β-LCR, which 
contains five DNase I hypersensitive sites; HS1-5 (Fig.1.5). HS1-4 are hypersensitive 
to DNase I in erythroid cells, whereas HS5 is ubiquitous in many non-erythroid cells. 
The hypersensitive site cores are 200-300 bp which are highly conserved between 
species. The core sequences contain binding sites for ubiquitous and erythroid 
specific transcription factors (Hardison 2001). 
It is proposed that this upstream region is responsible for activation of the β-globin 
gene locus by initiating and/or maintaining an open state of chromatin around the 
β-globin gene cluster and acting as an enhancer element of the globin genes 






Figure 1.5 The human β-globin gene locus on chromosome 11. Arrows indicate DNase I 
hypersensitive sites. (G. Stamatoyannopoulos 2005). 
 
The β-LCR is unique to other cis-acting regulatory elements as it can activate 
independent of position, as demonstrated in mice studies. Deletions of the β-LCR in 
transgenic mice results in a reduction of globin gene expression by 100-fold (Bender 
et al. 2000). However, when the β-LCR coupled with a β-globin gene is transfected 
into transgenic mice, this results in full expression of the gene, independent of the 
site of integration in the host genome (Grosveld et al. 1987). Moreover, deletion of 
individual HS sites prove that an intact LCR is necessary for full positional 
independent activation of the globin genes, therefore the HS sites act as a single 
unit (Milot et al. 1996). This highlights the importance of the LCR and globin gene 
co-operation in gene expression. 
The HS sites themselves have individual functions, acting in cis to the β-globin gene 
locus; HS5 is thought to act as an insulator or ‘boundary element’ (Li & 
Stamatoyannopoulos 1994). HS5 protects the locus from the negative effects of 
neighbouring closed chromatin (Harju et al. 2002) and insulates a specific 
chromatin domain, thereby regulating a steady state between open and closed 
chromatin (Gribnau et al. 2000). HS2 functions as an enhancer element and HS3 
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acts as an activator of ε-globin and γ-globin gene expression (Navas et al. 1998), by 
exerting chromatin opening and remodelling activity (Ellis et al. 1996). 
 
1.3.2 Globin gene activation by the β-LCR 
Several models have been proposed to explain how the β-LCR functions to activate 
the downstream globin genes and of these, the looping model is the most widely 
accepted (Fig. 1.6). This model suggests that the HS sites of the β-LCR fold into a 
holocomplex, bringing the LCR closer to the appropriate gene and thereby the 
transcription factors bound to the LCR are delivered to the gene locus to interact 
with the basal transcriptional apparatus and activate globin gene expression (Ellis et 
al. 1996; Fraser et al. 1993; Stamatoyannopoulos 2005; Wijgerde et al. 1995) .  
Studies have demonstrated the interaction of the LCR with downstream globin gene 
promoters via the looping model. Carter et al. (2002) used an RNA fluorescence in 
situ hybridization (FISH) method called RNA TRAP to tag and recover chromatin near 
the murine β-globin gene which recovered HS1, HS2 and HS3 together with the β-
globin gene. This demonstrated that the HS sites and β-globin gene were in close 
proximity. A further study used chromatin conformation capture (3C) to measure 
the proximity of LCR sequences and active globin genes in erythroid cells. Clustering 
of active regulatory elements at these sequences was referred to as an active 
chromatin hub (ACH) (Tolhuis et al. 2002). 
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1.4 Globin gene switching 
 
 
1.4.3 Gene switching mechanisms 
To explain how certain genes are switched off while others remain turned on, two 
mechanisms of gene switching are thought to be responsible for turning genes off; 
autonomous silencing and gene competition. Gene competition was first 
investigated in transgenic mice in which the β-LCR was linked to either the γ-globin 
(µLCR Aγ) or the β-globin (µLCR β) gene, alone. In both cases genes failed to show 
developmental expression, i.e. the β-globin gene was expressed in cells throughout 
all developmental stages including the embryonic cells. In other words, β-globin 
gene expression throughout development was as it would be in adult cells. The γ-
globin genes were also expressed in adult cells (Enver et al. 1990; 
Stamatoyannopoulos 2005).  
Figure 1.6 The looping model of gene activation at the β-globin locus. The LCR holocomplex is formed 
with transcription factors and other transcriptional apparatus. The holocomplex loops over the globin 
genes, bringing the transcriptional apparatus closer to the globin genes for transcription of the 
preferential gene (th  β-globin gene i  this example). Image adapted from Vieira et al. 2004. 
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When the LCR, γ and β genes were linked together in the same construct                
(µLCR Aγψβδβ), developmental expression of the genes followed. The γ-globin gene 
was predominantly expressed in embryonic erythrocytes and the β-globin gene was 
highly expressed in adult mice erythrocytes. γ and β-globin genes were expressed 
similarly in fetal liver erythroblasts, similar to the human perinatal stage (Enver et 
al. 1990). The investigators concluded that the γ and β genes compete to interact 
with the LCR (Enver et al. 1990). During fetal life, proximity to the β-LCR leads to 
preferential expression of the γ-globin gene. During adult life the γ-globin gene is 
autonomously silenced and the LCR interacts with the next downstream gene i.e. β-
globin.  
Similar experiments in transgenic mice showed that mice carrying the embryonic, ε-
globin gene do not express the gene at all, but when the ε-globin gene is linked to 
the LCR (µLCR ε) the gene is expressed at high levels, indicating the ε-gene 
expression is dependent on the LCR. At the same time, expression was nil in yolk 
sac erythropoiesis, suggesting all the components needed to turn off a gene are to 
be contained within the gene or adjacent sequence. This concept is called 
‘autonomous silencing’ (Raich et al. 1990). Transcription factors bind on silencing 
sequences on proximal and distal ε-globin gene promoters to form a silencing 
complex which turns off ε-globin gene expression by disrupting interactions 
between the gene and LCR (Stamatoyannopoulos 2005). Autonomous silencing is 
thought to be the principal mechanism to turn off genes, though gene competition 




1.5 Transcription factors at the β-globin locus 
Transcription factors play an important part in gene regulation at the β-globin 
locus. The HS sites all share a core sequence ~250 nucleotides long, which is 
studded with motifs for transcription factors. The HS sites contain binding sites for 
erythroid specific transcription factors NF-E2, GATA-1 USF, Sp1 and KLF1 (Harju et 
al. 2002).  
NF-E2 is an erythroid-specific DNA-binding protein that recognizes motifs 
(GCTGA(G/C)TCA) in the 5’HS2 of the β-globin LCR (Talbot & Grosveld 1991, 
Stamatoyannopoulos et al. 1995). Here, the NF-E2 binding sites are important for 
transcriptional activation and formation of HS sites in the LCR (Forsberg et al. 2000; 
Ney et al. 1990). Experimental evidence also shows NF-E2 binding sites are 
important for chromatin remodelling activity and necessary for ε-globin gene 
expression and formation of HS2 (Gong et al. 1996). 
GATA-1 is also an erythroid specific transcription factor required for globin gene 
switching and erythroid cell maturation. It is a member of the GATA zinc finger 
family of transcription factors which bind to nucleic acid consensus sequence 
(T/A)GATA(A/G) (Evans & Felsenfeld 1989; Tsai et al. 1989). GATA-1 binds to sites in 
the globin gene promoters and HS site cores of HS1-5 which contain the GATA-1 
recognition sequence (Orkin 1992). GATA-1 can also act as an activator when bound 
to the γ-globin gene promoter or HS1-5 (Jane & Cunningham 1996; J. A. 
Stamatoyannopoulos et al. 1995).  
GATA-1 is also an activator of the ε-globin gene but acts as a repressor of ε-globin 
when bound to the ε-globin gene silencer with transcription factor YY1 (Kellum & 
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Schedl 1991; J. Li et al. 1998). GATA-1 is known to interact with itself and other 
transcription factors like SP1 and KLF1 (Merika & Orkin 1993). 
Krüppel-like factor 1, KLF1 (previously known as erythroid Krüppel-like factor, EKLF) 
was identified by subtractive hybridization and found to be an erythroid cell-specific 
transcription factor, homologous to the Krüppel family of transcription factors 
which have roles in cell proliferation, differentiation and survival (Miller & BIeker, 
1993). KLF1 contains three zinc fingers at the C-terminus which bind to a CACCC 
sequence. CACCC sequences are repeated in erythroid enhancers and promoters, 
including the β-globin gene promoter (Miller & Bieker, 1993). This sequence is 
noted as a site of point mutations that give rise to β-thalassaemia. 
 It is reported by Feng et al. (1994) that KLF1 is unable to transactivate in the 
presence of these point mutations due to a decrease in binding affinity for these 
target sites. The KLF1 protein binds to the β-globin promoter with 8 fold higher 
affinity than to the γ-globin promoter (Donze et al. 1995). These studies showed 
KLF1 as a stage-specific, β-globin-specific transcription factor and proposed that it is 
most likely an important factor in the fetal to adult (γ to β) haemoglobin switch.  
Further studies in mice revealed that KLF1-/- mice die around day 14-15 of gestation 
due to anaemia caused by the failure to express β-globin. Moreover, the embryos 
showed features of β-globin deficiency as found in β-thalassaemia. KLF1-/- embryos 
appeared normal during embryonic yolk sac stage of haematopoiesis, but became 
fatally anaemic during early fetal life, at the precise time of the switch from 
embryonic to fetal-liver erythropoiesis (Nuez et al. 1995 & Perkins et al. 1995). 
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The activation of the different β-globin like genes is mediated in part through the β-
globin LCR region (Chapter 1.3.2). KLF1 binding enhances the interaction between 
the β-globin promoter and the LCR and so the interaction between the γ-globin 
promoter and LCR decreases (Miller & Bieker 1993, Donze et al. 1995). 
The human β-globin locus was studied in KLF1 knockout/human β-locus transgenic 
mice (Wijgerde et al. 1996). The ε and γ globin genes were expressed normally in 
KLF1-/- foetuses, with a complete lack of β-globin expression. In KLF1+/- /β-globin 
transgenic mice, there was a shift in the γ to β ratio caused by an increase in the 
number of actively transcribed γ genes and a decrease in transcribed β genes. The 
authors proposed that the reduction in KLF1 in the KLF1+/- mice reduced the time 
the LCR was in complex with the β-globin gene. Because KLF1 does not directly bind 
γ-globin, an increase in γ-globin is due to the LCR being less occupied with β-globin, 
therefore less β-globin activation and more interaction is formed between the LCR 
and γ-globin (Wijgerde et al. 1996). This was accompanied by changes in chromatin 
structure at the β-globin promoter, and HS3 of the β-LCR. 
Following this work, KLF1 was found to be required for the activity of 5’HS3 of the 
β-globin LCR by binding directly to the core fragment within HS3 (Tewari et al. 1998, 
Gilemans et al. 1998). Increasing levels of KLF1 lead to changes in the balance from 
γ to β-globin gene expression, which results in an earlier switch of the globin genes 
and the amount of KLF1 also influences the rate of the switching process (Tewari et 
al. 1998).  
These studies, collectively demonstrate the importance of KLF1 in the γ to β globin 
switch and LCR-β-globin gene interactions. 
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Recently it has been proposed that KLF1 has a direct role in BCL11A activation. Borg 
et al (2010) mapped the cause of HbF persistence in a Maltese family to 
chromosome 19 and found a heterozygous truncated KLF1 mutation in family 
members with high levels of HbF. When they looked at BCL11A expression, it was 
downregulated in these family members; moreover, γ-globin expression was 
upregulated. The same group demonstrated that KLF1 knockdown in human 
erythroid progenitor cells resulted in an increase in γ-globin and a decrease in 
BCL11A. The opposite effect was observed with full length KLF1 expression in 
individuals with high HbF, i.e. downregulation of γ-globin and upregulation of 
BCL11A. Furthermore, KLF1 binding was shown at the BCL11A promoter, 
demonstrating the direct role of KLF1 on BCL11A. These findings conclude that HbF 
persistence here is caused by KLF1 haploinsufficiency. These findings were 
confirmed by others (Zhou et al. 2010), and now propose a new model for globin 
regulation (Fig. 1.7). 
 




1.6 The Haemoglobinopathies 
 
The two commonest inherited disorders of haemoglobin that impact global health 
are β-thalassaemia and sickle cell disease (SCD). Both disorders arise from 
mutations in the β-globin gene locus (Steinberg 2001). 
An estimated 300,000 new-borns with these disorders are born worldwide, 
annually. These are prevalent in tropical and sub-tropical regions where carriers 
have a survival advantage to falciparum malaria, but these disorders have spread to 
most countries by population migration. β-thalassaemia is most common in Asia, 
the Mediterranean and Middle East, and SCD predominates in Africa (World Health 
Organization, fact sheet No.308, Jan 2011) 
SCD is caused by a point mutation in the 6th codon of the β-globin gene in which ‘T’ 
is substituted for ‘A’, changing a glutamic acid residue into a valine residue (Pauling. 
et al, 1949), and resulting in an altered β-globin chain, referred to as sickle globin 
(βS) (Marotta 1977). Two βS chains combine with two α-globin chains and make up a 
variant haemoglobin molecule called sickle haemoglobin (HbS- α2β2
S). This HbS is 
less soluble in its deoxygenated state and polymerises, causing a distorted, sickle 
like shape of the red blood cells. These sickle cells become trapped in the 
circulation causing clinical manifestations such as ischaemic organ damage and 
episodic pain crises (Fig. 1.8). Sickled cells are also highly fragile with a shortened 
lifespan, leading to haemolytic anaemia (Stuart & Nagel, 2004). 
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 Figure 1.8 Appearance and passage of red blood cells through vessels in normal (A) and sickle cell 
disease (B) scenario. (Adapted from National Heart Lung and Blood Institute, 2011). 
 
β-thalassaemia is characterized by a quantitative deficiency of the β-globin chain, 
caused by a wide array of mutations, mostly all of which affect the β-globin locus. 
The majority of mutations are point mutations within the gene and its immediate 
flanking sequences (Forget 2009). 
Lack of its partner β-globin chains, leads to an accumulation of free α-globin chains 
which aggregate in red blood cell precursors, forming inclusion bodies and causing 
apoptosis, ineffective erythropoiesis, peripheral haemolysis and reduction in Hb 
synthesis (Thein 2002). Some red blood cells that make their way to circulation 
show microcytosis and other deformities and are eventually hemolysed. 
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Erythropoiesis is thus expanded to compensate for the lack of functional red blood 
cells and causes hyperplastic marrow; an increased proliferation of red blood cells 
in the bone marrow (Bank 2005, Stamatoyannopoulos 1992).  
 
1.7 Fetal haemoglobin and the hereditary persistence of fetal 
haemoglobin 
Fetal Hb (HbF; α2γ2) has a much higher affinity for oxygen than the adult form of Hb 
(HbA; α2β2), and is the dominant form of Hb expressed during fetal life. The switch 
from fetal to adult Hb is not complete; background levels of fetal Hb continue to be 
produced in adult life with the majority of the healthy adult population having HbF 
levels of ≤0.6% of total Hb (Thein & Menzel 2009).  
Hereditary persistence of fetal haemoglobin (HPFH) is the term used to describe a 
condition in which high γ-globin expression persists into adult life, resulting in 
elevated HbF. Broadly speaking, there are two groups of HPFH; pancellular, 
referring to the even distribution of HbF in erythrocytes, with a clearly recognisable 
increase of 10-35% HbF in heterozygotes. These are caused by mutations (deletions 
or point mutations in the γ-globin promoter) affecting the β-globin gene cluster 
(Forget 1998).  
The second group is referred to as heterocellular hereditary persistence of fetal 
haemoglobin (hHPFH) reflecting the uneven distribution of HbF among the red 
blood cells. Individuals with heterocellular HPFH represent the upper tail of the 
natural continuous distribution of HbF with HbF levels >0.8%. Heterocellular HPFH 
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is inherited as a complex trait. Recently three major quantitative trait loci (QTLs) 
have been identified including a QTL on the β globin cluster, represented by the 
Xmn1-Gγ site (Craig et al. 1996; Thein & Weatherall 1989; Thein et al. 2007; Menzel 
et al. 2007). Erythrocytes in which HbF is high enough to be detected are 
designated ‘F’ cells (Boyer et.al 1975). 
 
1.7.1 Stress erythropoiesis 
At times when the demand for oxygen is greater, such as anaemia and tissue 
hypoxia (during fetal development), erythroid progenitor cells, induced by an 
increase in EPO, have the ability to rapidly proliferate, releasing large numbers of 
erythrocytes into circulation. This process is called ‘stress erythropoeisis’. A γ-globin 
to β-globin switch also occurs within early progenitor cells (Papayannopoulou et al. 
1986). While we see a small number of F-cells in normal erythropoiesis, during 
stress erythropoiesis more cells terminate maturation prematurely, while still 
expressing γ-globin, and are released into circulation while still expressing 
predominantly HbF as F-cells, thus increasing HbF levels (Stamatoyannopoulos 
2005). 
Raised HbF is clinically beneficial for people affected with β-globin deficiencies such 
as β-thalassemia or SCD. In β-thalassemia, the γ-globin chains combine with 
redundant excess α-globin chains thus reducing the α/β chain imbalance that 
underlies the severity of anaemia in β-thalassaemia (Thein 2002). In the case of  
SCD, the rate of HbS polymerisation is dependent on the concentration of HbS in 
the red blood cells, so an increase in non-sickle Hb, for example, an increase in fetal 
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Hb, shifts the reaction dynamics away from polymerisation and ameliorates the 
disease symptoms (Noguchi 1984). At the same time γ-globin also has an inhibiting 
effect on HbS polymerisation. 
For these reasons, higher levels of HbF have ameliorating effects in SCD and β-
thalassaemia, and so, reactivation of HbF synthesis is an important approach for the 
treatment of these haemoglobinopathies. 
 
1.7.2 Reactivation of HbF 
Hydroxyurea is an agent used to induce HbF levels in patients by increasing F-cells 
in circulation which results in increased HbF. Hydroxyurea has been used to treat 
SCD patients since the early 1990s, but seems to have variable effects in increasing 
HbF in β-thalassaemia patients. Currently many drugs are under investigation for 
use as HbF inducers, but none are close to being used as therapeutics for 
haemoglobinopathies. This makes understanding the γ-globin to β-globin switch 
and control of HbF production ever more important. Understanding the 
mechanisms behind this can lead to targeted therapies for the treatment and even 
cure of β-haemoglobinopathies. 
 
1.8 Quantitative trait loci influencing HbF levels 
A quantitative trait locus (QTL) is a region of DNA that is associated with a particular 
phenotypic trait, which in this case is HbF. QTL can often be found at regions within 
a gene, thus identifying candidate genes contributing to the phenotype. 
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Three loci associated with HbF levels have recently been mapped by genetic 
studies; Xmn1-Gγ polymorphism at the β-globin gene cluster, HBS1L-MYB intergenic 
polymorphism (HMIP) on chromosome 6q and BCL11A on chromosome 2p  (Craig et 
al. 1996; Thein & Weatherall 1989; Thein et al. 2007; Menzel et al. 2007). 
Multiple factors contribute to the variance in HbF levels in the population, including 
age, sex (2%) and environmental factors (9%), but an overwhelming 89% is 
attributed to genetic factors (Fig 1.9). The Xmn1-Gγ polymorphism at the β-globin 
locus accounts for up to 10% of the F cell variance in the general population (Craig 
et al. 1997; Thein 2002). However, more than 35% of the genetic variance in F cell 
levels is controlled by the other two loci; HMIP (19%) and BCL11A(15%) , which are 
unrelated to the β-globin locus (Thein 2002, Menzel et al. 2007).  
 
 
Figure 1.9 Factors contributing to the overall variance in HbF levels in the northern European 
population, highlighting the three main QTL identified to date (Figures based on Garner et al. 2000 & 




1.8.1 Chromosome 11 Xmn1-Gγ polymorphism 
The Xmn1-Gγ polymorphism on chromosome 11 is caused by a C-T polymorphism 
at position -158 upstream of the Gγ-globin gene. Xmn1-Gγ has long been implicated 
as a QTL influencing HbF production through clinical and family studies. This 
polymorphism is present in about 30% of the population, and results in a slight 
increase in HbF levels in this group. However, the presence of this polymorphism in 
SCD and β-thalassaemia patients results in even higher HbF levels. (Thein et al 
1987). 
1.8.2 6q23 HBS1L-MYB intergenic region 
The QTL for fetal haemoglobin on chromosome 6q23 was identified in a large 
consanguineous Asian-Indian family with β-thalassaemia and co-inherited hHPFH, by 
genome wide linkage analysis (Craig et al. 1996; Thein & Weatherall 1989). The 
family was first described in 1989 (Thein & Weatherall, 1989) through the 
propositus who was homozygous for β-thalassaemia and yet had an extremely mild 
clinical disease and HPFH (Thein et al. 1994). Several family members with or 
without β-thalassaemia had raised levels of HbF, up to 3.4% in normal members 
and up to as much as 24% in β-thalassaemia heterozygotes (Thein et al. 1994) 
Fine mapping with 210 family members brought the associated area to a 1.5Mb 
region (Garner et al. 1998), in which lie 5 protein coding genes; ALDH8L, HBS1L, 
MYB, AHI1 and PDE7B (Close et al. 2004) (Fig.1.10). Three of these genes; HBS1L, 
MYB and AHI1 are expressed in erythroid cells. None of these genes harboured any 
causative mutations and so it was proposed that the causative genetic variants may 
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be in the regulatory and non-coding regions and affect transcription of the genes 
rather than altering the gene function itself.   
It may be that differences between the mRNAs of these genes in individuals with 
elevated HbF and individuals with normal levels of HbF may relate to sequence 
variants in the regulatory regions of these genes. This led to the investigation of the 
expression patterns of the genes in the 6q23 locus in the erythroid precursor cells 
of individuals with and without elevated HbF levels, by quantitative reverse 
transcription PCR (Jiang et al. 2006). 
This study revealed both MYB and HBS1L were down-regulated in individuals with 
elevated HbF, making them candidate genes involved in the regulation of fetal 
haemoglobin.  
K562 cells transfected with human cDNA of MYB and HBS1L showed that over-
expression of MYB inhibits γ-globin gene expression, but HBS1L over-expression 
had no effect. This suggests that MYB may be the influencing factor at this QTL by 
acting as a negative regulator of the γ-globin gene (Jiang et al 2006). 
 
1.8.2.1 MYB 
The MYB gene (also known as c-Myb) was first recognized as the gene transformed 
by the avian myeloblastosis virus (AMV) which caused erythroblastic and myeloid 
leukaemia in quails and chickens (Oh & Reddy, 1999). The MYB gene is highly 
conserved through evolution (Lipsick, 1996); the major product of the human gene 
is a 75kDa nuclear protein of 636 amino acids. The protein is expressed in most 
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haematopoietic tissues and is highly expressed in immature haematopoietic cells 
(Gonda et al. 1982, Westin et al. 1982). Efforts were made to identify MYB target 
genes, by measuring differentially expressed genes between MYB-/- null mutants 
and wild-type cells. The GATA-1 transcription factor was found to be down-
regulated in the MYB-/- cells, giving clues to the involvement of MYB in regulation of 
haematopoiesis (Lin et al. 1996).  
Further evidence for this is seen when MYB knockout mice died in utero after day 
15 of gestation due to severe anaemia (Mucenski et al. 1991). MYB is critical 
transcription factor in haematopoiesis, being involved in both cell proliferation and 
differentiation. It is required for maintenance of proliferation by exerting a direct 
role in cell cycle control (Oh et al. 1999). MYB is highly expressed in immature 
haematopoietic cells and is down-regulated as the cells differentiate (Westin et al. 
1982), expression of MYB blocks differentiation in neuroblastoma cell lines, 
suggesting down-regulation of MYB is also required for terminal differentiation (Oh 
et al. 1999).  
So far there has been no evidence for a direct role of MYB on the regulation of the 
γ-globin gene. It has been proposed that MYB influences HbF levels via altering 
erythroid kinetics. It is evident that MYB is involved in cell proliferation and 
differentiation; low MYB levels correlate with accelerated erythroid maturation 
(Jiang et al. 2006). HMIP block 2 SNPs (see chapter 1.8.3) that are highly associated 
with raised F cells are associated with reduced erythrocyte count, increased 
erythrocyte volume and increased platelet count (Menzel et al. 2007), suggesting 
that the HbF QTL has a pleiotropic effect on haematopoiesis.   
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Another mechanism whereby MYB can affect γ-globin production is via KLF1 
activation of BCL11A (Bianchi et al. 2010) as discussed on page 14. 
Raised HbF is a feature in some cases of Trisomy 13 (Huehns et al. 1964). Sankaran 
et al. (2011) mapped this elevation of HbF in Trisomy 13 cases to chromosomal 
band 13q14 which encodes two microRNAs: miR-15a and miR-16-1, which are 
expressed in erythroid precursor cells. Increasing the expression of these miRNAs in 
haematopoietic progenitor cells by 1.5 fold (as would be expected in a trisomy), 
resulted in an increase in γ-globin levels by 2.4 fold, which suggests that the 
elevated HbF levels seen in Trisomy 13 cases are likely due to increased expression 
of these miRNAs. Interestingly, when the authors investigated the targets of these 
miRNAs, the MYB gene was found to have two conserved 8mer miR-15a/16-1 
targeting sites. MYB protein levels were reduced with even a slight increase in the 
expression of these miRNAs. This study further supports the role of MYB in the 
regulation of HbF, and its importance in erythropoiesis.  
 
1.8.2.2 HBS1L 
The HBS1L gene is mostly uncharacterised in humans. It is the human ortholog of 
the Sacharomyces cerevisiae HBS1 gene, encoding a GTP-binding protein which 
shares structural features with elongation factor eEF-1A and release factor 3 (eRF3) 
families (Wallrapp et al, 1998). Its role, if any, and to what extent in the regulation 




1.8.3 HBS1L-MYB intergenic polymorphisms (HMIP) 
The 6q23 QTL story continued with further analysis of the region in Northern 
European twin pairs, by a high resolution association study (Thein et al. 2007). The 
study revealed multiple single nucleotide polymorphisms (SNPs) associated with 
HbF levels in the region between HBS1L and MYB. The SNPs reside in 3 linkage 
disequilibrium (LD) blocks (HMIP block 1-3) 79 kb within the intergenic region. HMIP 
blocks 1-3 account for all F cell variance at the 6q23 locus. HMIP blocks start 188bp 
upstream of the HBS1L gene and end 45 kb upstream of the MYB gene, both genes 
are transcribed in opposite directions (Figure 1.10). A 24 kb segment, starting 33 kb 
upstream of HBS1L represents HMIP block 2.  Twelve markers in HMIP block 2 
showed strongest associations with HbF (P values of 10-50-10-75) and all the SNPs in 
this block are in complete linkage disequilibrium.  
These SNP associations with HbF levels were later confirmed in sickle cell disease 
patients (Lettre et al. 2008) 
In further studies the SNPs in HMIP 2 were found to have pleiotropic effects on 
other haematological parameters in healthy Northern Europeans, including 
erythrocyte count, erythrocyte volume, platelet count and monocyte count (Menzel 
et al. 2007). 
It is our thinking that HMIP block 2 in the HBS1L-MYB intergenic region contains 
regulatory elements which influence HbF levels, possibly by regulating the control 






Figure 1.10 View of the QTL in chromosome 6q23 and HMIP blocks 1-3. Image adapted from (Thein 
et al. 2007). 
 
1.8.4 2p15 BCL11A locus  
To identify additional QTLs, our group conducted a genome wide association study 
(GWAS) in a Northern European cohort of 179 individuals with contrasting extreme 
F cell values (Menzel et al. 2007) 
This study picked up the already known HbF associated loci at the Xmn1-HBG2 site 
and HMIP on chromosome 6q23, and in addition identified a third, previously 
unknown QTL on chromosome 2p15, close to a gene encoding the zinc finger 
protein BCL11A.  A further panel of 142 SNPs were genotyped which uncovered two 
clusters of association (Fig. 1.11a). The strongest association lay at a 14 kb region in 
intron 2 of BCL11A, with the second cluster spanning 67 kb in the 3’ region of 
BCL11A, 8-7 kb downstream of exon 5 (Menzel et al. 2007). 
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The 2p15 QTL was estimated to contribute 15% of overall trait variance for HbF 
levels (Menzel et al. 2007). The peak of association within BCL11A was later 
confirmed by other groups (Lettre et al. 2008, Sedgewick et al. 2008, Uda et al. 
2008). Uda et al. screened 4,000 Sardinians with varying HbF levels, finding 
association at the three major loci, with the strongest association for HbF levels 
with SNP rs11886868 (Figure 1.11a) in intron 2 of the BCL11A gene (p<10-34). 
To investigate if the influence of BCL11A on HbF modulates clinical phenotypes in β-
thalassaemia, the same group genotyped SNP rs11886868 in 52 patients with β-
thalassaemia intermedia and 74 with β-thalassaemia major. The ‘C’ allele of 
rs11886868, which is strongly associated with HbF was significantly more frequent 
in patients with β-thalassaemia intermedia, leading to the conclusion that the 
variant rs11886868 ‘C’ allele influences a milder phenotype.  
The authors further studied the effect of BCL11A in a cohort of 1,242 sickle cell 
disease (SCD) patients and found the rs11886868 ‘C’ allele was also strongly 
associated with increased HbF in these patients (p<10-20). Thus, BCL11A has 
important effects in haemoglobinopathies as well as non-anaemic individuals. 
Sedgewick and colleagues (2008) through genetic association studies investigated 
the association of the known BCL11A SNPs in 3 different racial populations; 250 
Chinese patients with β-thalassaemia major, 113 Thai patients with β-thalassaemia 
or HbE heterozygotes and 255 African Americans with SCD. Strong association of 
SNP rs766432 in intron 2 of BCL11A was found in all 3 groups.  
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In the Chinese β-thalassaemia group, individuals with the ‘CC’ genotype of rs766432 
had twice as much HbF and F cells as those with an ‘AA’ genotype. Of the African 
American group with SCD, homozygotes for the ‘C’ allele of the same SNP had an 
average 7% HbF and homozygotes for the ‘A’ allele had an average 3% HbF. This 
suggests that the ‘C’ allele of rs766432 affects HbF levels in these populations. 
SNP rs11886868 found by Uda et al. in the Sardinian and SCD patients is also in the 
same LD block in Africans and Europeans. This shows that the most important SNPs 
involved in HbF regulation at this locus are located within intron 2 which may be a 
regulatory motif. 
In a third genome wide association study the BCL11A SNP rs11886868 was shown 
to have strong association with HbF levels in the 1,275 African Americans with SCD 
(Lettre et al. 2008). In addition SNPs rs4671393 and rs7557939 (in LD with 
rs11886868) were genotyped and showed stronger association with HbF levels than 
rs11886868 in both African Americans and Brazilians with SCD.  
These studies collectively confirm that the genetic variants at the 2p15 QTL 
influence HbF levels in SCD and lie within intron 2 of the BCL11A gene. 
 
1.8.4.1 BCL11A  
In 2000, Nakamura and others made efforts to identify possible leukaemia disease 
genes in BXH2 mice, which highly develop leukaemia on retro-viral integration. 
This was done using a method called retro-viral tagging. Retro-viruses integrate into 
the mouse haematopoietic cell DNA, disrupting the function of near-by genes, 
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resulting in the development of leukaemia. Therefore, by tagging the integration 
sites, isolating the DNA and sequencing, the genes targeted by the retro-virus could 
be identified. Identifying such retroviral integration sites by retroviral tagging 
meant that possible disease genes could be found. 
One such common site of retroviral integration in BXH2 leukaemic mice cells is 
Ectopic viral integration site 9 (or Evi9). By chromosomal and physical mapping this 
site was located to chromosome 11 and because this was near the c-rel proto-
oncogene this suggested that Evi9 may represent a new leukemia disease gene. 
The same group demonstrated that a gene at Evi9 encodes a zinc-finger protein 
which binds to another zinc-finger protein called BCL6- which is a known human B-
cell proto-oncogene product, so the new gene at Evi9 was coined BCL11A. Apart 
from the zinc finger domain it appeared BCL11A was distinct from anything in the 
current databases and two alternatively spliced BCL11A isoforms were identified by 
RT-PCR. 
Saiki et al. (2000) investigated the possible role of BCL11A in the human 
haematopoetic system. This was done by screening a human fetal brain cDNA 
library using a mouse BCL11A cDNA fragment as a probe and a 3,063 nucleotide 
cDNA clone was produced. The sequence was analysed and revealed that human 
BCL11A encodes a 797 amino acid protein. Compared to the mouse cDNA sequence 
the human cDNA encodes 35 additional amino acids at the N-terminus but other 
than this, both mouse and human proteins share 99% homology.                           
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Chromosomal localization by flourescence in situ hybridization (FISH) mapped the 
gene to chromosome 2p13 (Saiki et al. 2000). This site had previously been 
described in a chromosomal translocation with chromosome 14q32, in two children 
with chronic lymphocytic leukemia (Fell et al. 1986). The region of chromosome 2 
was not characterised at the time. 
BCL11A is a highly conserved zinc finger gene and is expressed in haematopoietic 
progenitors, is down-regulated during myeloid differentiation (Saiki et al. 2000) and 
is essential for normal B and T cell development (Liu et al. 2003). BCL11A binds to 
GC-rich motifs and mediates transcriptional repression (Senawong et al. 2005, 
Sankaran et al. 2008).  It is also involved in lymphoid malignancies through 
translocation or amplification events (Fell et al. 1986, Richardson et al. 1992, 
Satterwhite et al. 2001). BCL11A mutations have also been associated with B-cell 
malignancies (Liu et al. 2006).  
It has been shown that BCL11A acts as a repressor of HbF production; using BCL11A 
knockdown, the levels of γ-globin and HbF were dramatically elevated in erythroid 
cells (Sankaran et al. 2008). However, this did not affect overall erythroid 
differentiation. BCL11A has also been shown to bind to discrete sites in the β-globin 
gene cluster, indicating a direct role of BCL11A in globin gene regulation (Sankaran 
et al. 2008). 
More recent studies using a human β-globin locus YAC transgene and a BCL11A-/- 
mouse, showed that in the absence of BCL11A, developmental silencing of the 
human γ-globin genes is impaired in the definitive erythroid lineage. Intermediate 
silencing in a BCL11A+/- mouse suggests that not only is BCL11A a developmental-
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stage specific repressor but the effect is quantitative (Sankaran et al. 2009). Also, 
differences in BCL11A expression patterns between mouse and humans may be 
responsible for their divergent expression of β-like globin genes (Sankaran et al. 
2009). 
At least four BCL11A transcripts exist, giving rise to different protein isoforms; 
extra-long (XL; 5.9kb, 125kD), long (L; 3.8kb, 100kD), short (S; 2.4kb, 35kD) and 
extra short (XS; 1.5kb, 25kD). Exons 1& 2 are common to all four isoforms, exon 3 & 
4 to isoforms XL, L and S. Isoforms L and S share exon 5 and isoform XS contains 
exon XS (Liu et al. 2006) (Fig. 1.11b). 
a)  
b)  
Figure 1.11 a) QTL in chromosome 2- BCL11A. Highest scoring SNPs indicated at intron 2. b) Four 
major BCL11A isoforms, XL, L, S and XS (Images adapted from a) Thein et al. 2009, b) Liu et al. 2006) 
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The role of these different isoforms is largely unclear. Studies have shown that the 
shorter isoforms appear in primitive erythroid cells, whereas the larger forms 
appear in later developmental stages of erythroid maturation, when γ-globin 
expression is reduced (Sankaran et al. 2008).  
BCL11A represents a possible therapeutic target for the treatment of β-
haemoglobinopathies and studies are already showing its potential in reactivation 
of HbF and correcting the phenotypes of SCD in mouse models. Xu et al. (2011) 
employed SCD mice containing targeted deletions of murine α and β globins and 
the addition of human fetal and adult globin transgenes which were also null for 
BCL11A (SCD/ BCL11A -/- mice).   In these SCD/BCL11A -/- mice, haematological 
parameters including RBC counts and Hb content were corrected and sickle cells 
were absent in comparison to SCD mice. SCD/ BCL11A -/- mice showed increased 
expression of γ-globin, strong pancellular staining for HbF and F-cells accounted for 
85.1% of total RBCs. These findings demonstrate that SCD phenotypes can be 








1.9 HbF in MDS & Myeloid leukaemia 
Raised HbF levels have also been observed in some acquired physiological 
conditions like pregnancy and acute blood loss and are associated with acquired 
malignancies of haematopoietic cells including myelodysplastic syndrome (MDS); a 
disorder of the myeloid cells which causes ineffective haematopoiesis. (Bourantes 
et al. 1991, Weatherall 1975). 
A case study by Craig et al. (1996) examined F-cell production in a large group of 
MDS patients and found 62% of patients had raised levels of F-cells. 24.7% of MDS 
patients had higher HbF levels compared to 11% of normal individuals with raised 
HbF. Moreover, 61% of MDS patients with abnormal karyotypes have raised HbF 
(>5%). The group also reported that all four cases with monosomy 7 or 7q deletions 
had significantly higher F-cell levels. 
Juvenile myelomonocytic leukaemia (JMML) is a rare mixed form of 
myelodysplastic/myeloproliferative disorder affecting young children (WHO 
classification, 2001). A key feature of JMML is elevated HbF. Chromosome 7 
abnormalities and monosomy 7 is also common in JMML (25-30% of cases) 
(Emanuel 2008) and high levels of HbF in JMML is an indicator for poor prognosis, 
though why this is so, is unclear. 
A recent study by Yin et al. (2009) measured gene expression in 285 patients with 
acute myeloid leukaemia (AML). A subset of AML patients with monosomy 7, 
associated with poor disease outcome showed high expression levels of BCL11A. 
Patients with JMML also showed high levels of BCL11A expression. Elevated HbF is 
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almost invariable in JMML, and yet BCL11A expression is seen to be elevated which 
is contrary to its role, as we know it, of acting as a repressor of HbF production. 
Considering the current knowledge of myeloproliferative disorders and myeloid 
leukaemia, there seems to be a strong association with HbF levels and monosomy 7 
in myeloid disorders, and more recently a possible role for BCL11A in these 
disorders. 
BCL11A occurs as several protein isoforms (as discussed earlier). The shorter 
isoforms (L and S) appear to be restricted to primitive erythroblasts, and the full 
length (XL) isoforms to the adult-stage erythroblasts. All forms have been shown to 
acts as transcriptional repressors, but their functional overlap, interaction with each 
other and their individual roles remain to be discovered. 
It is possible that different isoforms of BCL11A are expressed in different tissues 
and may have different roles in different cell types. This could possibly explain the 
high levels of BCL11A expression seen in JMML and myeloid disorders with 
monosomy 7, despite the very high levels of HbF, and may also shed more light on 






1.10 Aims & Objectives 
The overall aim of this research was to characterise the two trans-acting candidate 
regions at 6q23 and 2p15 involved in the control of HbF production.  
1.10.1  6q 23, HMIP QTL 
Transcription factors are critical regulators of gene expression. I aimed to 
investigate if there is differential transcription factor binding at the HMIP locus 
through chromatin immunoprecipitation (ChIP-chip) studies in primary human 
erythroid progenitors from individuals with different HbF phenotypes and 
genotypes.  
1.10.2  2p15, BCL11A QTL 
The majority of my research concentrates on this QTL. Evidence suggests BCL11A 
acts as a transcription factor (Sankaran et al. 2008), and so I explored the role of 
BCL11A in this capacity at different loci involved in haemoglobin production, 
including the α and β-globin loci. I also investigated other important erythroid 
transcription factors including KLF1 and GATA-1 at these loci. 
The QTL at the BCL11A gene is mapped to a 14kb region within intron 2. I aimed to 
re-sequence this portion of the gene in individuals with high HbF and low HbF, to 
both confirm known, and identify any novel sequence variations between the 
extreme phenotypes. 
Different protein isoforms of BCL11A exist. In order to better understand the 
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2.1 Cell culture 
 
K562 cells (an erythroleukemia cell line originally isolated from a chronic myeloid 
leukemia patient in blast crisis) were maintained at 0.5-1 million/ml in RPMI 
medium (Sigma-Adrich, UK) supplemented with 10% FCS (PAA-laboratories, UK), 
2mM L-glutamine (Sigma-Aldrich, UK), 0.1mg/ml streptomycin and 18units/ml 
penicillin (Sigma-Aldrich, UK) and incubated at 37°C in 5% CO2. 
 
2.1.1 Two phase erythroid culture 
This liquid culture technique was adapted from the original method described by 
Eitan Fibach (Fibach et al. 1989), with modifications as detailed in Jiang et al. 2006. 
50mls of peripheral blood was collected and centrifuged to separate the blood 
components. The yellow plasma interface is the component containing 
lymphocytes and progenitor cells and is called the buffy coat. This was collected 
and layered onto a density gradient centrifugation liquid- Histopaque-Ficoll (Sigma-
Aldrich, UK) and centrifuged to separate red and white blood cells. The lymphocytes 
and other mononuclear cells remain at the plasma-histopaque interface from 
where they are collected and washed in PBS. Cells are counted and cultured in 
flasks at 1-2 million/ml in Phase I media (Stem Span Medium [Stem Cell 
Technologies, Canada], 10U/ml penicillin, 10µg/ml streptomycin, 1µg/ml 
cyclosporin A, 25ng/ml interleukin 3 [IL-3; Sigma, UK] and 50ng/ml human stem cell 
factor [SCF; Sigma, UK]) at 37° in 5% CO2.  
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24 hours later the entire culture suspension is moved to a fresh flask, leaving 
behind the adherent monocytes in the first flask. 
After 7 days in phase I, the culture is moved to a 50ml falcon tube, centrifuged and 
the cell pellet re-suspended in Phase II media (Stem Span Medium, 10U/ml 
penicillin, 10µg/ml streptomycin, 2U/ml human recombinant erythropoietin [EPO; 
Sigma, Poole UK] and 50ng/ml SCF) and maintained at a concentration of 1 
million/ml for up to 20 days. 
 
2.1.2 Cell morphology 
Cytospins of erythroid cells were made by spinning 1x105 cells in a 100-200µl 
volume onto glass slides. Slides were then stained using a Giemsa staining set 
(Hema “Gurr”, VWR, UK.), and viewed with 40x objective under the microscope 
(Zeiss Axiolab). 
 
2.1.3 Flow cytometry  
Fluorescence activated cell sorting (FACS), a specialized type of flow cytometry, was 
used to test erythroid cell purity. Glycophorin A (GPA) and CD71 are human red 
blood cell membrane proteins (Furthmayr et al. 1975). GPA protein is highly 
expressed on the surface of mature erythroid cells, while CD71 is expressed in 
proliferating haematopoietic cells. Detection of GPA and CD71 indicates the purity 
of late erythroid progenitor cells in the culture. 
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2µl of fluorescent antibodies against human CD71 (fluorescein isothiocyanate [FITC] 
conjugated, BD Biosciences, Oxford, UK) and anti-human glycophorin A (GPA, R-
phycoerythrin [RPE] conjugated, DAKO, Glostrup, Denmark) were added to 1x106 
erythroid cells that had been washed in PBS and then re-suspended in 100µl of PBS. 
Both antibodies were added for a double staining and one sample was prepared 
without antibody to serve as a negative control. Cells and antibody were incubated 
for 30 minutes in the dark, followed by two washes with PBS and cells are then re-
suspended in a final volume of 1ml PBS containing 1% formaldehyde and 0.1% 
bovine serum albumin (BSA). FACS analysis of 10,000 cells was acquired using 
Becton Dickinson flow cytometer and CellQuest software (Becton Dickinson, UK). 
 
2.2 Western blotting 
 
2.2.1 Protein extraction 
5x106 cells were collected, centrifuged and re-suspended in 250µl RIPA cell lysis 
buffer (20mM Tris-HCl, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1mM 
EDTA 0.1% SDS) and 12.5µl 20X protease inhibitor (1 Complete EDTA-free Protease 
Inhibitor Cocktail tablet [Roche, UK] dissolved in 500µl H2O). 
Protein concentration was measured by spectrophotometry at absorbance 280 
(Protein A280) and diluted in RIPA  buffer and 20µl of 4X SDS loading buffer (10ml 
1M Tris, 1ml 10% SDS, 10ml glycerol, 250µl 2-mercaptoethanol, 250µl 1% 
Bromophenol Blue, 4ml H2O) to a final concentration 1µg/µl in 100 µl volume.  
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2.2.2 Protein electrophoresis and transfer 
Samples were denatured for 10 mins in a heat block at 95°C. 25µg of each protein 
(25µl) and  10µl SeeBlue protein marker (Invitrogen) were loaded on a NuPAGE 10% 
Bis-Tris precast gel (Novex, Invitrogen) in MOPS SDS running buffer (Novex, 
Invitrogen). The gel was run overnight at 20V using the Novex Invitrogen Surelock 
X-Cell electrophoresis system, to separate proteins. 
Proteins were transferred from gel to nitrocellulose membrane (Amersham Hybond 
ECL membrane, GE Healthcare) for 2 hours at 55V (X-Cell blot module, Novex 
Invitrogen) in transfer buffer (3.04g tris, 14.5g glycine, 200mls methanol 800mls 
H20). Non-specific binding was blocked with 5% dry milk (Marvel) in PBS-Tween (5 
PBS tablets dissolved in 5mls Tween-20 and 995mls H20) for minimum 2 hours at 
4°C with constant rolling.  
 
2.2.3 Antibody probing 
The membranes were then incubated overnight in 5% milk containing the primary 
antibody at 4°C with constant rolling.  
The following morning after washing 3 times for 10 mins in PBS-Tween the 
membranes were incubated in a secondary antibody with 5% milk at room 
temperature for 1 hour 15mins with constant rolling. This was followed again by 




2.2.4 Target protein detection 
Target proteins were detected by an enhanced chemiluminescence kit (Amersham 
ECL Plus western blotting detection system, GE Healthcare). Following 
manufacturer’s instructions, the membrane was incubated with ECL reagents for 5 
mins and drained off. The membrane was wrapped in Saran wrap and placed in an 
exposure cassette.  In a dark room the membrane was exposed to high 
performance chemiluminescence film (Amersham Hyperfilm ECL, GE Healthcare) for 
varying amounts of time (between 10 seconds to 3 mins) and the film was 
developed using the Compact X4 X-Ray film processor (Xograph Imaging Systems, 
UK) 
To re-probe with another primary antibody, membranes were blocked again in 5% 
milk before incubating in primary antibody overnight as before. 
 
2.3 Chromatin immunoprecipitation (ChIP) 
ChIP experiments were carried out using the EZ-ChIPTM kit (cat# 17-371) according 
to manufacturer’s protocols with minor modifications (modifications kindly 
provided by Dr. David Garrick from the MRC molecular haematology unit, Oxford). 





2.3.1 Cell-protein cross linking 
The process of cross-linking links DNA to protein so that the DNA can be co-
precipitated with the protein using a specific antibody. 5x107 erythroid cells were 
taken for cross-linking in 10ml growth medium with 1% formaldehyde (Sigma-
Aldrich, UK), and incubated for 10 min at room temperature with rolling.  125mM 
Glycine was added to quench the formaldehyde and then cells were washed in 5ml 
of cold PBS with protease inhibitors and centrifuged at 1000 rpm for 10 min at 4°C, 
twice. The pellets were divided into 5 aliquots of 1x107 and stored at -80°C.  
 
2.3.2 Cell lysis 
5x107 cross-linked cells were lysed in 1ml SDS-lysis buffer (EZ-Magna ChIPTM Kit 
(cat.# 17-409) (Upstate-Millipore, UK) with protease inhibitor and incubated on ice 
for 15 min, vortexing every 5 mins. Cells were spun at 800 xg for 5 mins at 4°C and 
the pellet re-suspended in 1ml nucleus lysis buffer (EZ-Magna ChIPTM kit) with 
protease inhibitors. 
 
2.3.3 Chromatin fragmentation by sonication 
Cell/nuclei lysates (5x107 cells/ml equivalent) were sonicated with a Vibra Cell 
sonicator (Sonics, US) set at 40 % efficiency for 10x15 seconds using a small probe 
(2mm in diameter) to achieve DNA fragment lengths of 1000-200bp. The samples 
were kept on ice during sonication and left to rest on ice for 30secs in-between 
each round of sonication to avoid overheating with protein denaturation as a 
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consequence. To remove insoluble material, samples were spun at 10,000 xg for 10 
min and the supernatant was moved to a new tube.  
 
2.3.4 Gel analysis of sonication 
For analysis of sonication efficiency, 5µl of sonicated material was collected and de-
cross-linked over night at 65 °C after the addition of 90µl of H2O and 4µl 5M NaCl. 
Following de-crosslinking, 1µl RNase A (10µg/µl) was added and the sample was 
incubated at 37 °C for 30-60 min to degrade RNA. Subsequently 2µl of 0.5M EDTA, 
4µl Tris-HCl (1 M, pH 6.5) and 1µl Proteinase K (10µg/µl) was added followed by a 2 
h incubation at 45 °C to degrade proteins. 10µl of chromatin samples were analysed 
on 1-1.5 % agarose gels. 
 
2.3.5 Immunoprecipitation (IP) 
Sonicated chromatin was diluted 10 times in ChIP dilution buffer supplied in the kit 
and provided with protease inhibitors. 2 x 10µl of sample was removed and stored 
at 4°C as input sample and kept until the following day. 
10-15µg of antibody was added to the diluted chromatin (equivalent to 1x107 cells) 
for each IP and 40µl of protein-G magnetic beads (EZ-Magna ChIPTM kit) were added 
and incubated overnight at 4°C on rotation. In the cold room (to keep proteases 
cold) beads were pelleted using a magnetic tube rack and the supernatant was 
discarded. Beads were then washed by re-suspending the bead pellet in 1ml of 
wash buffers supplied in the kit, incubated for 5 min at 4°C and pelleted again by 
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standing for 1 min on the magnet, the wash was discarded and pellet re-suspended 
in the subsequent wash buffer and incubated again. Washes were performed in the 
following order: 
1. Low salt immune complex wash buffer (1ml) 
2. High salt immune complex wash buffer (1ml) 
3. LiCl immune complex wash buffer (1ml) 
4. TE buffer  (1ml)  
The last TE wash was performed at RT.  
To elute bound chromatin, 200µl of elution buffer (containing 10µg/ml Proteinase 
K) was added to re-suspend each sample and the two input samples from the 
previous day. All samples were incubated at 62°C for 3 hours with constant 
rotation. In this step the elution buffer separates the chromatin from the antibody 
and beads, the heat reverse-crosslinks the chromatin protein from the DNA and the 
Proteinase K treatment destroys the proteins. 
Samples were then incubated at 95°C for 10 min and the beads were pelleted using 
the magnetic rack, the DNA is now in the supernatant which is transferred to a 
fresh tube. 
 
2.3.6 Purification and ethanol precipitation of ChIP material 
200µl of 1:1 phenol/chloroform-isoamylalcohol mixture was added to samples. 
Samples were vortexed and spun at 13000 rpm for 1 min. The aqueous top layer 
was transferred to a fresh tube containing 20µl of 3M sodium acetate and 20µg 
59 
 
glycogen (Roche, UK). DNA was precipitated at -20°Covernight and pelleted by 
centrifugation at 14 000 rpm for 40 min at 4°C. Pellets were washed with 150µl 70% 
EtOH followed by centrifugation at 14 000 rpm for 10 mins at 4°C. Dried pellets 
were re-suspended in 20µl of water. 
2.3.7 Analysis of enrichment by real time PCR 
Purified ChIP DNA was measured using the NanoDrop® Spectrophotometer ND-
1000 (NanoDrop Technologies, USA) and analysed for fold enrichment with control 
primers (Appendix 1, Table 11.2) using real time SYBR-Green PCR which measures 
double stranded DNA generated. 0.4-0.5μl (~20ng) of ChIP sample and input sample 
was mixed with 2-4pmol each of forward and reverse primer, and 5μl of SYBR-
Green PCR master mix (Applied Biosystems, UK) in a 10 µl reaction volume. All 
samples were analysed in duplicate using standard real time PCR conditions; 50°C 
for 2 min, 95°C for 10 min, 95°C for 15 sec and 60°C for 1 min repeated for 40 
cycles. 
Fold enrichment for an antibody (ab) at a specific primer target (amplicon) in ChIP 
samples was calculated relative to input DNA and normalised to a sequence in the 
NEFM gene according to the following formula: 
 




2.3.8 Whole Genome Amplification of ChIP material 
ChIP material was amplified using the GenomePlex® Whole Genome Amplification 
(WGA) kit (Sigma-Aldrich, UK) according to a protocol specifically developed for 
ChIP material (www.sigma-aldrich.com). 100ng of DNA was used for amplification 
which generated 1-5μg of amplified material (measured by NanoDrop®). Amplified 
material was purified using the QIAquick PCR Purification Kit (Qiagen, UK) according 
to the manufacturer’s protocol with the exception that the buffer PBI, which is not 
recommended for microarray applications, was substituted for buffer PB. 
2.4 Microarray analysis of ChIP material (ChIP-chip)  
Sample labelling, hybridization, washing and microarray scan was performed using 
the NimbleGen system (Roche-NimbleGen, Madison, US, 
http://www.nimblegen.com) according to manufacturer’s protocol (NimbleGen 
array’s user guide for ChIP applications).  
 
2.4.1 Labelling of ChIP material and microarray hybridisation 
1μg each of input DNA and ChIP DNA was diluted to a 40μl volume with H20. 40μl 
of Cy3 or Cy5 fluorescently labelled random primers were added to the input and 
ChIP samples, respectively. The Cy3 and Cy5 labelled random nonamers (TriLink 
Biotechnologies, USA) were previously diluted in random primer buffer (125mM 
Tris-HCl pH 7.4, 12.5mM MgCl2 and 0.18 % β-mercaptoethanol) to a concentration 




Labelling reactions were set up in 100μl volumes. To each sample 10μl of 50X dNTP, 
2μl (100 U) Klenow fragment (New England Biolabs, UK) and 8μl of Sigma water was 
added. Sample mixtures were incubated for 2 h at 37°C which labelled the ChIP 
DNA by primer extension. 
Reactions were stopped by the addition of 10μl 0.5 M EDTA. 11.5μl NaCl (5M) and 
110μl isopropanol was added to each sample to precipitate the DNA for 10 mins at 
room temperature. Samples were centrifuged at 12 000 rpm for 10 mins. DNA 
pellets were washed with 500μl 80% ice-cold ethanol. Labelled DNA samples were 
re-suspended in 4.5μl water. 0.5μl of labelled DNA was diluted 10 x and DNA 
concentrations were quantified using the Nanopdrop spectrophotometer. As Cy 
primers are light sensitive samples were protected from light during all steps. 
 
2.4.2 Microarray Design 
Custom built microarrays were generated, and were composed of 50mer 
oligonucleotide probes that tile non-repetitive genomic sequence of: 3.8 Mb of 
6q23, including the intergenic region associated with HbF between co-ordinates 
chr6:133,500,000–137,300,000; 1.1 Mb of chr11p including the entire β globin 
cluster region from co-ordinates chr11:4,730,996–5,732,587 and 500 kb of the 
telomeric region of chromosome 16, including the α globin Encode region starting 




2.4.3 ChIP-on-chip hybridisation 
7.2μg of Cy3 input and Cy5 ChIP labelled DNA were mixed together and made up to 
6μl with sigma water.  The hybridisation reaction mixture contained labelled 
alignment oligos which hybridize to alignment features on the arrays needed for 
data extraction, 2x hybridisation buffer (11.8μl) and hybridisation component A 
(4.7μl), (NimbleGen Hybridisation kit). 15.6μl of this mixture was added to the 6μl 
sample and incubated at 95°C for 5 mins and then at 42°C until ready to load onto 
the array slide. 
Hybridisations were done using NimbleChip x1 Mixers and the NimbleGen 
hybridisation system. The microarray slide has a hybridisation chamber over the 
array to which the hybridisation solution is loaded at a fill port on the mixer. Once 
the slide is in place and the sample loaded to cover the whole array (16-20μl of 
sample) the machine is switched on to mix the hybridisation solution over the array 
by a pumping mechanism which allows even hybridisation at 42 °C for 16–20 h. 
Microarrays were washed using wash buffers, wash tanks and slide rack, all 
supplied in the NimbleGen Hybridisation kit. 25μl DTT (1M) was added to 25mls of 
each wash buffer. Microarrays and mixers were first disassembled in wash buffer 1 
previously warmed to 42 °C. Following disassembly, the microarrays were washed 
by vigorous and constant agitation for 2 min and 15 s in wash buffer 1, 1 min in 
wash buffer 2 and 15sec in wash buffer 3. Immediately after the last wash, the 




2.4.4 Scanning of microarrays  
The hybridised microarrays were placed in the GenePix 4000B scanner and scanned 
using GenePix software (Molecular Devices, Sunnyvale, USA) according to the 
NimbleGen Arrays protocol and images saved for analysis. 
 
2.4.5 Microarray data analysis 
Microarray data was extracted and analysed using the NimbleScan software 
according to the NimbleGen Arrays protocol. The NimbleScan software aligns the 
probes on the microarray to a design file describing probe location using the 
locations of alignment features on the array. The program then calculates a signal 
ratio of input and ChIP sample for each probe on the array and extracts statistically 
significant peaks from the ratio. These peaks indicate binding sites. Once this data is 
converted into track files, these can be uploaded and viewed on the UCSC genome 
browser (genome.ucsc.edu, assembly March 2006, NCBI36/hg18), thus displaying 
binding signals across the genome. In this way multiple tracks can be viewed in a 










2.5 Gene expression 
 
All DNA, RNA and protein concentrations were measured on a Nanodrop® 2000 
spectrophotometer (Thermo Scientific). Thermal cycler used throughout was the 
PTC-200 Peltier thermal cycler (MJ Research). 
 
2.5.1 Total RNA extraction 
Total RNA was extracted from cells using TRI Reagent (Sigma, Poole, UK) according 
to manufacturer’s instructions. 1ml of TRI-reagent was used to lyse between 5-10 
x106 cells, for less than 5x106 cells a minimum of 0.5ml of TRI-reagent was used. 
RNA was resuspended in 100µl of DEPC-treated water (Applied Biosystems, 
Ambion) and stored at -80°C. RNA was quantified by Nanodrop. The absorption 
maximum of RNA is 260nm and the ratio of the absorbance at 260 and 280nm is 
used to assess the RNA purity of a sample. The Nanodrop measures the absorbance 
from the region of 200nm to 350nm to determine the RNA concentration and 
purity.  
 
2.5.2 Reverse Transcription 
First strand cDNA was generated from RNA by using SuperscriptTM III Reverse 
Transcriptase (Invitrogen, Paisley, UK). Reactions were set up with 500ng RNA, 1μl 
oligo dT (0.5μg/μl) and 1μl dNTPs (10mM) in a 13μl volume and incubated on a PCR 
block at 65˚C for 5 min. 4μl of 1st strand buffer (5x), 1μl DTT (0.1 M), 1μl 
SuperscriptTM III RT (200U/μl) and 1μl water were added to a final volume of 20μl. 
The reactions were incubated on a PCR block at 50˚C for 60 mins followed by 70˚C 
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for 15 mins and cooling to 4˚C. cDNA was diluted with water to a total volume of   
50μl and stored at -20°C. 
 
2.5.3 TaqMan Real Time PCR  
Custom designed primers and probes for TaqMan real time PCR analysis were 
ordered from Applied Biosystems (UK) (Appendix 1, Table 11.1). Primer probe mixes 
for BCL11A (Hs00256254- Invitrogen, UK) and housekeeping genes HPRT1 
(Hs99999909) and GAPDH (Hs99999905) were ordered as ready-made gene-
expression assays from Applied Biosystems. 10µl reactions were set up with 2μl 
cDNA, 1.5pmol each of forward and reverse primer, 2pmol of fluorescent probe and 
5μl of TaqMan PCR master mix (Applied Biosystems, UK) and run on an ABI Prism 
7900HT Sequence Detection system (Applied Biosystems, UK) under the following 
conditions; 
Step1) 50°C for 2 min,  
Step 2) 95°C for 10 min,  
Step 3) 95°C for 0.15 min and 60°C for 1 min repeated for 40 cycles. 
Real time PCR measures the number of cycles to reach the threshold of 
fluorescence detection. The cycle at which the threshold is reached is called the 
threshold cycle or CT, which provides a value for the starting copy number of a DNA 
target. A lower CT value means fewer amplification cycles were required to reach 
the threshold of fluorescence detection and therefore the higher the starting 
amount of our specific DNA sequence. 
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Gene expression was calculated as fold change between levels of the target gene in 
the sample versus negative control and then normalized to the housekeeper genes. 
 
2.5.4 DNase Treatment 
RNA samples from overexpression plasmid transfected K562 cells were DNase 
treated for removal of plasmid DNA using Ambion® TURBO DNA-free™ Kit (Applied 
Biosystems, Ambion) prior to reverse transcription. 5µl of 10X TURBO DNase buffer 
and 1µl of TURBO DNase was added to 5µg of RNA in a 50µl reaction volume and 
incubated at 37°C for 30 mins. 5µl of DNase inactivation reagent was added to the 
reaction and incubated for 5 mins at room temperature and mixed at least 3 times 
over the 5 min incubation period. Finally sample was centrifuged at 10,000 xg for 
1.5 min and transferred to a fresh tube.  
 
2.6 DNA Sequencing 
2.6.1 Standard PCR and gel purification 
DNA was specifically amplified by standard PCR. 25µl reactions were set up with 5µl 
of DNA, 10µM each of forward and reverse primers (Appendix 1, Table 11.3, 11.4 & 
11.7), 10mM dNTP, 2.5µl MgCl2, 2.5µl 10X buffer and 0.4µl of AmpliTaq Gold. The 
reactions were run on a thermal cycler under the following conditions; 
Step1) 94°C for 10 min  
Step 2) 94°C for 0.30 min  
Step 3) 55°C for 0.30 min 
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Step 4) 72°C for 0.30 min 
Step 5) Repeat steps 1-4 for 30 cycles 
Step 6) 72°C for 2 min 
PCR product was initially visualized by running a small amount of the product on an 
agarose gel. Once PCR quality was confirmed, all the remaining PCR product was 
run on a fresh agarose gel. The gel was then placed on a UV imager, the product 
was visualized and the band(s) scored with a scalpel. Using the incisions as precise 
markers the product was cut out, placed in a 1.5ml eppendorf tube. The gel was 
dissolved and DNA purified as per the protocol outlined in the Promega Wizard SV 
Gel and PCR Clean-up System instruction booklet. DNA concentration was then 
measured by the Nanodrop®. 
 
2.6.2 Cycle sequencing 
Sequencing reactions were carried out using the ABI PRISM BigDye Terminator v3.0 
Ready Reaction Cycle Sequencing Kit following protocols as outlined in the user’s 
manual. 20µl reactions were set up with 200-300ng of DNA, 3.2pmol primer and 4µl 
of 5 X buffer and 2µl of Terminator Ready Reaction Mix. Reactions were run on a 
thermal cycler according to manufacturer’s protocol (Applied Biosystems, 
Warrington, UK). 
2.6.3 Ethanol precipitation 
Reactions were transferred to 1.5ml eppendorf tubes containing 16µl deionized 
water and 64 µl of 95% ethanol. Samples were vortexed and incubated at room 
temperature for 15 mins, followed by a 20 minute spin at maximum speed. 
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Supernatant was discarded and sample washed with 400µl of 70% ethanol and spun 
again for 10 mins. Supernatant was again discarded and pellets dried at room 
temperature.  
 
2.6.4 Electrophoresis and data collection 
The pellets were re-suspended in 20µl of formamide, vortexed well and spun down. 
Samples were then transferred to a 96-well plate and pulse spun to 1000rpm. 
Samples on the plate were then denatured for 2 minutes at 95˚C on the thermal 
cycler. The plate was then set up and run on the sequencing machine 3130xl 
Genetic Analyser (ABI Prism by Applied Biosystems) as per the manufacturer’s 
instructions. Data was analysed using the DNA sequence analysis programme 
Sequencher® version 4.6 (Gene Codes Corporation, Ann Arbor, MI USA 
http://www.genecodes.com). 
 
2.7 Vector construct preparation 
2.7.1 Restriction enzyme digests 
Typically, restriction enzyme digests for 1μg of DNA were set up in a total volume of 
25μl with 5 units of enzyme (New England Bioland, Ipswich, UK and Roche, Burgess 
Hill, UK) and the supplied buffer. Bovine serum albumin (BSA) was added according 
to manufacturer’s protocol. Restriction digests were incubated in a water bath at 37 





30µl gel-purified RT-PCR products were A-tailed by adding 1U of AmpliTaq Gold, 
PCR buffer, 10mM dATP and incubating at 72˚C for 15 minutes. 
2.7.3 Ligations 
To avoid religation of vectors digested with single restriction enzymes, 2 units of 
alkaline phosphatase (Roche, Burgess Hill, UK) per 1μg of DNA was added to the 
restriction digest reaction. 
Ligations were set up with an approximate vector to insert molar ratio of 1 to 3 in a 
total volume of 10μl. After the addition of 1 unit of T4 DNA ligase and T4 DNA ligase 
buffer (Roche, UK), the ligations were left in room temperature for 1 h followed by 
incubation over night at 4°C. Ligations were transformed the following day. 
 
2.7.4 Heat shock transformations 
Competent DH5α bacteria (Invitrogen, Paisley, UK) were used for transformations. 
Typically 5μl of ligation mixture was added to 50μl bacteria and incubated on ice for 
30 min. Bacteria were heat-shocked at 42°C for 30 s and chilled on ice for 5 min. 
Following the addition of 250μl SOC medium (Invitrogen, Paisley, UK), the bacteria 
were incubated in 37°C with gentle shaking at 250 rpm. Transformed bacteria were 
grown on LB-agar plates with the addition of appropriate antibiotics and incubated 




2.7.5 Colony PCR 
A small amount of bacterial colony was picked with a sterile tip and resuspended in    
10μl of water in PCR tubes. Following incubation at 96°C for 5 min, 15μl of PCR 
master mix (0.7pmol/μl forward primer, 0.7pmol/μl reverse primer, 4.1mM  MgCl2, 
0.3mM dNTP, 2.5μl 10 x Taq gold buffer, 1.25 units Taq Gold) was added to each 
tube to obtain standard concentrations of reagents in a 25μl reaction volume. A 
standard PCR program was run and PCR products were analysed for positive clones 
on agarose gels. 
 
2.7.6 Plasmid preparations 
Bacteria for plasmid preparations were grown in LB medium in a shaking incubator 
at 37 °C. Plasmids were extracted from bacteria using a QIAprep® Spin Miniprep kit 
(Qiagen, Crawley, UK), or a HiSpeed Plasmid maxi kit (Qiagen, Crawley, UK) 
according to manufacturer’s protocol. 
All vector constructs were prepared in the group laboratory by Dr Steve Best. 
 
2.8 Transfection of K562 cells by electroporation 
4 x106 cells were centrifuged and re-suspended in 400µl of serum free RPMI culture 
medium per sample. Cells were transferred to electroporation cuvettes. 5µg of 
vector construct was added to the cells, the cuvette was capped and mixed gently. 
Transfection was achieved by electroporating cells using BioRad Gene Pulser® II 
following manufacturer’s instructions at 960µF capacitance and 250V per pulse. 
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Following electroporation, cells were transferred to 10 ml of complete RPMI culture 
medium in small culture flasks and incubated at 37°C for 48hrs. 
2.9 Luciferase reporter assays 
Firefly and renilla luciferase levels were measured 24-36 h after electroporation 
using the Dual-Glo Luciferase Assay System (Promega, Southampton, UK). Cells 
were counted and the amount of cells used for assay was based on the lowest 
count. Cells were spun down at 1000 rpm for 5 min and resuspended in additive-
free medium to obtain a volume of 225μl. Readings were initially taken for firefly 
luciferase and then for renilla luciferase. For each electroporation, triplicates of 
75μl were loaded on a 96 well plate and 75μl firefly of luciferase reagent was 
subsequently added to each well. Reactions were left at room temperature for 10 
min before luciferase levels were measured using a Lucy2 luminometer (Anthos, 
Engendorf, Austria) or a DTX 880 Multimode Detector (Beckman Coultier, High 
Wycombe, UK). Following Luciferase readings, 75μl of Renilla luciferase reagent was 
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 3.1 INTRODUCTION 
 
In the past, in vitro haematopoiesis has been studied mostly by semi-solid culture 
systems in which colonies are formed from erythroid progenitor cells. Because the 
cells are immobilized in this culture system, it makes it very difficult to analyse the 
growth kinetics and characterise the developing cells. To study erythroid cell 
development, a more robust method to overcome the limitations of semisolid 
cultures was required and a new method was introduced by Fibach and colleagues 
in 1989. The group proposed a two-phase liquid culture system that supports the 
growth and maturation of human erythroid progenitor cells.  
The conditions of culture systems are developed to mimic the natural environment 
of erythropoiesis. The cells yielded using these culture systems are very similar to 
their in vivo counterparts. This means morphological changes and gene expression 
changes accompanying erythroid differentiation can be studied in these cells.  Due 
to their leukemic origin and extensive culturing, cell lines such as K562s have lost 
many features of the native erythroid cell and are therefore an unsuitable model to 
study erythroid gene regulation. The Fibach liquid culture system is therefore an 
ideal system for providing erythroid progenitor cells at different stages of erythroid 
differentiation. Primary human erythroid cells can be obtained from healthy 
individuals and patients for in vitro genomic studies such as transcription factor 
binding by chromatin immunoprecipitation. 
Erythroid progenitor cells can be derived from bone marrow aspirates, fetal livers, 
cord blood and peripheral blood (PB). There are certain advantages to using 
peripheral blood over other sources including ease of access. More importantly, PB 
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contains a homogenous population of BFUe, providing a more uniform starting 
point for cultures (Fibach et al. 1989).  
The first phase isolates erythroid progenitor cells by depleting all other cell types 
while expanding growth of the progenitor cells. The second phase promotes the 
proliferation and maturation of the erythroid progenitor cells. This selection is 
achieved by administration of key growth factors including erythropoietin (EPO) at 
the different stages of the culture.  
For the work presented in this thesis I used the Fibach two-phase liquid culture 
system with some variations as previously established by our group (Jiang et al. 
2006). The main difference is that I used a semi-synthetic Stem Span medium (Stem 
Cell Technologies) instead of the fetal calf serum originally described by Fibach (et 
al. 1989). I also substituted the 5637 cell conditioned medium originally described; 
with interleukin-3 (IL-3) and stem cell factor (SCF). 
Firstly, density gradient centrifugation using Histopaque-Ficoll (Sigma-Aldrich, UK) is 
used to separate the blood components. Red blood cells are heavier and sink to the 
bottom and the mononuclear cells remain in a layer at the plasma-histopaque 
interface (buffy coat), from where they are collected. The buffy coat contains a 
small number of progenitor cells and mostly monocytes and lymphocytes. These 
cells are now suspended in Phase I medium containing IL-3 and SCF which bind to 
their respective receptors on the surface of the erythroid progenitor cells and 
stimulate proliferation of the cells. The Phase I medium also contains Cyclosporin A, 
an immunosuppressive agent which causes depletion of the lymphocytes. 
Monocytes adhere to the bottom of the culture flask and are removed by 
transferring the culture suspension gently into a fresh flask. 
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Over 7 days the progenitor cells have had a growth advantage and are now 
transferred into Phase II medium. Phase II medium contains EPO which stimulates 
the proliferation and differentiation of erythroid progenitor cells, and 
dexamethasone which increases the sensitivity of the cells to EPO (Golde et al. 
1976). During incubation in Phase II medium, cells develop into mature erythroid 
precursor cells (Figure 1.4). 
For each ChIP experiment I required 106 cells and this culture method was the best 
to yield large numbers of pure erythroid cells. I assessed cell development 
morphologically by analysing cell cytospins. The purity and development of cells 
was further analysed by flow cytometry. The full methods are outlined in chapter 
2.1.1.  
Erythroid cultures used for representative cytospins and FACS analysis in results 
section 3.2 were done in collaboration with fellow PhD students Suleyman Aktuna 











3.2.1 Analysis of cell morphology 
 
In Phase II, proliferation of the erythroid progenitor cells were maintained at a cell 
count of 106/ml. Cell differentiation was monitored daily by cell cytospins (see 
chapter 2.1.2).  
Small round erythroid progenitor cells were visible in the culture from day 1 of 
Phase II (Figure 3.1) with the presence of some prepro-erythroblasts which 
increased in number by day 4. The cell cytospin taken on day 7 showed the majority 
of the cells in the culture were now pro-erythroblasts. Basophilic erythroblasts 
began to appear from day 10 which were distinctly smaller than the pro-
erythroblasts.  
As the cells developed into polychromatic erythroblasts (day 12) they reduce in size 
and the nuclei become more condensed. By day 16 the cells are smaller yet, with a 
pale cytoplasm as the dark nucleus moves to one side of the cell which is now called 
an orthochromatic erythroblast. Soon the nucleus is expelled from the cell as seen 







 Figure 3.1 Differentiation of primary human erythroid progenitor cells. Cytospins of cells taken in 
Phase II day 1-18 of a two-phase liquid culture system adapted from Fibach et al. (1989). 




3.2.2 Purity and differentiation of erythroid cells in Phase II of culture 
 
Cell differentiation and culture purity was further analysed by a specialised form of 
flow cytometry called fluorescence activated cell sorting (FACS). I used two human 
erythroid cell surface proteins as markers of cell development and purity; 
Glycophorin A (GPA) (DAKO, Glostrup, Denmark)  and transferrin receptor protein 1 
(CD71) (BD Biosciences, Oxford, UK) (Furthmayr et al. 1975). GPA is an erythroid 
specific protein and is up-regulated as the cells develop into erythrocytes. CD71 is 
highly expressed on the surface of proliferating haematopoietic cells, including 
erythroid progenitors during the early stages of development.  
 
Figure 3.2 Differentiation and purity of primary human erythroid progenitor cells by FACS analysis. 
Cells in Phase II day 4, 6, 10 & 16 of modified Fibach culture are double stained with antibodies 
against CD71 and GPA. The y-axis shows CD71 expression and the x-axis shows GPA expression. 
Lower left box: double negative cells. Upper left box: CD71 positive, GPA negative cells. Upper right 
box: GPA and CD71 positive cells. Lower right box: GPA positive, CD71 negative cells. Markers (black 
lines) separating each field were set according to single stained and unstained control samples from 
the same culture at each day. 
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As cells proliferated in the early stages of culture, CD71 expression on cells 
increased from 28% on day 4 to 97% on day 10, the maximum that it would reach 
(Figure 3.2).  
GPA is expressed later as the cells develop. We see a rapid increase in GPA 
expression between day 6, when 30% of cells analysed were positive for GPA and 
day 16 when we observed 90% of GPA positive cells. GPA positive, CD71 negative 
cells appeared after day 10 and by day 16 represented 15% of cells analysed (Figure 
3.2). CD71 is a non-specific marker, in that it is a marker for all proliferating cells 
and not just erythroid cells. GPA however is an erythroid-specific marker, and 
therefore is the more important factor to monitor. 
 
3.2.3 Gene expression profiles 
For ChIP experiments, I needed to harvest cells at the peak expression stage of the 
transcription factor to be analysed. I constructed expression profiles of the different 
genes by qPCR of RNA extracted from erythroid cells at different days of Phase II 
and reverse transcribed to cDNA. Ct values were normalised to the house-keeping 
gene HPRT and fold change in expression was calculated relative to day 4 (KLF1 and 
BCL11A) and day 6 (GATA1). 
KLF1 and BCL11A were up-regulated as cells developed, reaching the peak 
expression on day 10 (Figure 3.3). Day 10 also happens to be the peak expression of 
GATA-1.  
This data shows that all three genes of interest (KLF1, BCL11A and GATA1) are at 
peak expression around day 10 of culture in phase II. This coincides with high levels 
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Figure 3.3 Expression profiles of KLF1, BCL11A and GATA1 in primary human erythroid cells taken 
on different days of culture (Phase II). Analysed by qPCR in duplicate reactions using gene specific 
primers. Data was normalised to house-keeping gene HPRT and the first day on which cells were 











































For the purpose of ChIP experiments I needed a large number of a homogenous 
population of primary human erythroid cells at synchronised stages of expression. 
Removal of macrophages in the early stages of culture (Phase I day 1) led to the 
generation of a purer culture of erythroid cells. However, small numbers of 
macrophages are beneficial to erythroid cell development in vivo and in vitro 
(Chasis & Mohandas 2008, Leimberg et al. 2005) and this was previously 
demonstrated by our group in the following experiments.  
Monocytes in Phase I were depleted by use of a lysosomotropic agent, l-leucin 
methyl ester (LME), which causes selective death of monocytes in culture. LME 
treated cultures contained no macrophages on day 0 of phase II. A high amount of 
cell death was observed from day 6 of phase II with no viable cells visible on 
cytospins at day 10. In contrast, the control culture (no LME) had a small number of 
macrophages on day 0 of phase II and erythroid precursor cells had developed to a 
homogenous population of pro-erythroblasts at day 6.  
Cell differentiation in the control culture was, however, slower than that of 
previous cultures containing higher numbers of macrophages. The technique by 
which the majority of monocytes are removed and a small number of macrophages 
remain in culture that is achieved in this method (i.e. the transfer of the culture to a 





Culture purity was confirmed by FACS, showing 90% of cells were positive for GPA 
at day 10, the majority of which were morphologically homogenous. At day 10, 
there was a high level of transcription factors KLF1, BCL11A and GATA-1 expression. 
I conclude that Phase II day 10 of culture is the most appropriate time to harvest 
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The HBS1L-MYB intergenic region contributes 19% of the variation in HbF levels in 
healthy northern Europeans (Thein et al. 2007). SNPs that account for the effects of 
the 6q locus on HbF levels are distributed in 3 linkage disequilibrium blocks (HMIP1, 
2 and 3) which occupy a 79kb segment between the HBS1L and MYB genes. The 
SNPs showing the strongest association with HbF levels are found in block 2 
(HMIP2). 
Wahlberg et al. (2009) identified DNase I hypersensitive sites in HMIP block 2 
suggesting the presence of regulatory elements in the HBS1L-MYB intergenic 
region. I proceeded to analyse the region for transcription factor binding and 
chromatin modification by chromatin immunoprecipitation on microarray (ChIP-
chip). The use of microarrays would allow us to see a more extensive area of the 
6q23 locus.  
Chromatin immunoprecipitation is a method to study the interaction of proteins of 
interest with their target DNA sequences in vivo (Figure 4.1). Material used for ChIP 
experiments was harvested from primary human erythroid cell cultures at a time 
when our protein of interest is expressed. Expression profiles for each target 
protein to be studied were constructed. Primary human erythroid cells were 
cultured from whole blood using the method adapted from Fibach et al. (1989) and 
detailed in chapter 2.1.2. RNA was extracted from cells at different days of culture 
and reverse transcribed into cDNA. Using primers specific for each target gene, 
expression was measured by qPCR and I used this information to estimate the 
optimal day to harvest cells for ChIP experiments. 
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On harvesting, cells were cross-linked using 1% formaldehyde, this step fixes the 
proteins to the target DNA sequence in their native state. The material is then 
sonicated to shear the DNA to fragments between 200-1000bp (NimbleGen array’s 
user guide for ChIP applications). The material was then immunoprecipitated with 
an antibody to our specific protein of interest. Once the antibody is bound to its 
target protein, excess antibody is washed away and the antibody-protein-DNA 
material is reverse cross-linked, this time detaching the protein from its target DNA 
sequence.  
At the end of this step, we are left with DNA that has been specifically targeted by 
our protein using a specific antibody. The amount of DNA resulting from a ChIP is 
usually very low and to analyse this on a microarray I required 1.5µg of DNA 
(NimbleGen array’s user guide for ChIP applications). This ChIP DNA is amplified 
globally using a whole genome amplification kit (Sigma-Aldrich) before it is labelled 
with fluorescent dyes and hybridised to a custom micro-array. Our custom micro-
arrays contain several different loci of interest including the globin gene loci and 
the 6q23 locus. The micro-array is scanned and analysed using computer software 
(SignalMap and NimbleScan); the fluorescence signals detected indicate the binding 
sites of our protein of interest. The full ChIP-chip protocol is outlined in Chapter 2.3. 
GATA-1 is an erythroid specific transcription factor, required for globin gene 
regulation and erythroid cell maturation. The important regulatory role of GATA-1 
in erythropoiesis makes it an ideal candidate to study transcriptional activity at the 
6q23 locus. I decided to look at GATA-1 binding on the HMIP locus by ChIP-chip to 




Figure 4.1 Illustration of ChIP-chip protocol. Image adapted from ‘Genomic views of distant-acting 












4.2.1 DNA sonication 
 
Following crosslinking of primary human erythroid cells and cell lysis, the material 
was sonicated to shear the DNA. 1µl of the sonicated chromatin was run on a 1.5% 
agarose gel to confirm the size of the DNA fragments (Figure 4.2, lanes 2-3). Figure 
4.2 shows chromatin was successfully sheared to 100-600bp. 
 
 
                                           
Figure 4.2 Sonication of chromatin. Chromatin sample was run in duplicate (lanes 2 and 3) along 
with PhiX DNA marker (lane 1), on a  1.5% agarose  gel. Product size is as indicated in base pairs on 
the left of the image.  
 
4.2.2 Control test for GATA-1 enrichment 
 
Following confirmation of the chromatin size, I proceeded to immunoprecipitation 
using a ChIP grade anti-GATA1 antibody (M-20 sc1234, Santa Cruz). After reverse 
cross-linking and purification of the ChIP DNA, a small amount was tested for 
enrichment by SYBR-Green qPCR. Hypersensitive site 40 (HS-40) upstream of the α-
globin locus on chromosome 16 (α-HS40) is a known GATA-1 binding site and was 
used as a positive control in GATA-1 ChIP experiments. This step is a check point to 
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confirm if ChIP with the target antibody has been successful. On average, nine-fold 
enrichment was seen after ChIP with anti-GATA-1 antibody, as demonstrated in 
Figure 4.3.                                                     
 
                                   
Figure 4.3 Enrichment of α-HS40 to confirm GATA-1 ChIP (using antibody GATA-1 M-20 sc-1234, 
Santa Cruz) by SYBR-Green qPCR. Shown as fold enrichment, normalized to NEFM as a housekeeper 
gene and input sample (sample before ChIP with antibody). Datum is mean of at least 3 
experiments, +/- SE. 
 
After validating GATA-1 ChIP, I continued to process the remaining ChIP material for 
a global view of GATA-1 binding in the 6q23 intergenic locus (position chr6: 
135,373,000-135,582,000). Initial analysis was done using SignalMap (Roche, 
NimbleGen) where data extracted from the microarray scan on NimbleScan was 
mapped onto tracks to view our specific genomic regions. I then constructed our 
own tracks of the GATA-1 peaks at the 6q23 locus and surrounding area which were 
uploaded and viewed on the online UCSC genome browser (genome.ucsc.edu) 
which provides a more detailed view of the region, with the flexibility of viewing 
SNP tracks, conserved GATA-1 sites, hypersensitive regions, DNA sequence, other 
transcription factor sites, as well as many other tracks available, all in the same 












α-HS40 for GATA-1 
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ChIP-chip data to investigate AcH3, AcH4 and RNA polymerase II binding in the 6q 
intergenic region in primary human erythroid cells was obtained in the same way in 
collaboration with fellow student Karin Wahlberg (Wahlberg et al. 2009).  
 





Figure 4.4 ChIP-chip data for the HBS1L-MYB intergenic region. Results from ChIP-chip experiments 
for GATA-1 (M20,sc-1234, Santa Cruz), RNA polymerase II (Upstate), AcH4 (Upstate), and AcH3 
(Upstate) in primary human erythroid precursors. Covering 210-kb of 6q locus (position chr6: 135 
373 000-135 582 000) including part of the HBS1L gene, the intergenic region, and the MYB gene. 
The HMIP block 1, 2, and 3 are shown above indicated by the horizontal brackets. Also shown is 
conserved GATA-1 motifs and DNase I hypersensitive sites (as identified in hemin-induced K562 cells 





The intergenic region between the HBS1L and MYB genes showed strong signals for 
AcH3, AcH4, RNA polymerase II and GATA-1, indicating a high level of 
transcriptional activity in this area (Figure 4.4). AcH3 and AcH4, as well as RNA 
polymerase II signals were found around the promoters and coding region of the 
two flanking genes, which are both, highly expressed in human erythroid precursors 
cells. Generally there was strong AcH3 and AcH4 signal in the intergenic region, 
which was not seen anywhere else around the 6q segment. This indicates that the 
region is highly active in erythroid cells.  
Strong GATA-1 signals were found around the HBS1L and MYB gene area, but 
concentrated in the intergenic region. Three of the six strongest GATA-1 peaks 
found in HMIP2 coincide with DNase I hypersensitive sites previously identified in 
induced K562 cells, as a further indication of the functional regulatory role of this 
site (Wahlberg et al. 2009). Four of the strongest GATA-1 peaks in the intergenic 
region also coincide with conserved GATA-1 sites.  
Our ChIP-chip data strongly supports the hypothesis that the intergenic region 
between HBS1L and MYB contains a regulatory element which is likely to control 








4.2.4 GATA-1 binding at the 6q23 locus in extreme HbF phenotypes 
To further investigate this region, I decided to analyse the region in individuals with 
high and low HbF levels to identify any potential differences in GATA-1 binding 
between the two genotypes which may help to explain the difference in HbF levels. 
One individual was homozygous for all the SNPs associated with high HbF in the 6q 
region (blocks 1, 2 and 3) and was designated +/+, while the other was homozygous 
for the absence of the high HbF SNPs and was designated -/-. 
Primary erythroid cells were cultured from whole blood taken from the two 
individuals, both of whom were from the same family in which the QTL was first 
identified. ChIP-chip was carried out as previously described using the same anti-
GATA-1 antibody (M-20 sc1234, Santa Cruz). I performed two microarray 










                            
Figure 4.5 GATA-1 binding at the 6q23 QTL in erythroid precursor cells of individuals with high HbF, low HbF and normal levels of HbF, in duplicate 
(technical repeats on the same samples), by ChIP-on-chip analysis using NimbleGen custom microarrays. Red peaks represent GATA-1 binding, black arrows at 
the bottom indicate gene location; HBS1L and the MYB gene including the intergenic region between the genes. HMIP blocks 1-3 are shown by brackets 
above, DNase I hypersensitive sites are represented by broken arrows, and the blue dots at the bottom mark conserved GATA-1 binding sites at this region. 




GATA-1 signal was seen at the promoter region of the HBS1L gene in all 
individuals and not much signal anywhere else along the gene itself. In contrast, 
strong signal was found near the 5’ end of MYB and within the gene itself, which 
again was consistent in all individuals. 
In general, I found considerable GATA-1 binding in the HMIP region, particularly 
in the highly associated HMIP2 block. The ChIP data in Figure 4.5 highlights an 
area within the HBS1L-MYB intergenic region (grey bar) that showed differential 
binding; GATA-1 binding is seen in erythroid precursor cells of both individuals 
with low levels of HbF and with normal levels of HbF, but is completely absent in 
the individual with high HbF. This site lies within HMIP2 at HS3, one of the HbF-
associated SNPs (rs9494142) also lies within this block. This area also coincides 
with a conserved GATA-1 binding site. Other than this binding site, all other 
GATA-1 binding sites in the critical intergenic region were consistent in all 
individuals.  
Based on our earlier work (Figure 4.4) in collaboration with others (Wahlberg et 
al. 2009) and taken with the above data it is evident that this site may well 










Previously, genome wide association studies (GWAS) identified a QTL for raised 
HbF levels on chromosome 6. Further analysis revealed SNPs at a more precise 
location on chromosome 6q23, in the intergenic region between the HBS1L and 
MYB genes (HMIP). These SNPs lie in 3 linkage disequilibrium blocks, HMIP 1-3.  
HMIP2 accounts for the strongest effect on FC variance at this locus. Using 
chromatin immunoprecipitation experiments, I show that this area has 
significant histone acetylation and RNA polymerase II activity. I also show that 
several strong GATA-1 binding sites are concentrated within HMIP2, three of 
which coincide with DNase I hypersensitive sites. Such patterns of RNA 
polymerase II binding, histone acetylation and GATA-1 binding around DNase I 
hypersensitive sites is seen in known erythroid control regions, suggesting that 
this intergenic space may also be an active control region. 
A profile of GATA-1 binding was performed at the 6q23 locus in two individuals 
from the same family with phenotypes at the two extreme ends of FC trait and 
associated with contrasting genotypes. One independent individual with normal 
HbF levels was used as a control. 
This revealed similar GATA-1 binding patterns between the three phenotypes at 
the 6q intergenic region, except for one anomaly seen at HMIP2 which also 
coincides with a high scoring SNP (rs9494142) associated with HPFH.  GATA-1 
binds strongly at this site in the individuals with low HbF and normal levels of 
HbF, however there are no GATA-1 binding signals seen here in the individual 
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with raised HbF. This suggests that differential GATA-1 binding at the 6q QTL may 
contribute to the HbF phenotype. 
Although these binding signals were confirmed by two technical repeats on one 
biological sample for each individual (Figure 4.5), these results are not 
quantitative and should be validated by qPCR. Assays designed to measure the 
enrichment of target sequences bound by GATA-1 (Figure 4.4 & 4.5) would both 
quantify and validate this data. Further analysis of this region with more 
biological samples is also required to confirm these results. This work is currently 
on-going. 
Wahlberg et al. (2009) demonstrated that non-erythroid cells (HeLa cells) show 
substantially less H3 acetylation in the intergenic region, suggesting the 
transcriptional activity is indicative of a control element and is erythroid specific. 
HeLa cells do not express MYB and the lack of transcriptional activity in the 
region implies a link between the two, i.e. MYB expression and transcriptional 
activity in the intergenic region. 
Following this work, other groups are also interested in characterising the 
dynamics of the MYB locus, since our data implies a distal regulatory region 
controls the expression of this gene.  
Transcription factors including LDB1, GATA-1, FOG-1 and KLF1 are required to 
maintain chromatin looping to form an active chromatin hub (ACH) at the β-
globin locus to initiate transcription (Tolhuis et al. 2002, Drissen et al. 2004, 
Vakoc et al. 2005, Splinter et al. 2006, Song et al. 2007).  These LDB1 complexes 
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were found to bind at sites in the HBS1L-MYB intergenic region in MEL cells and 
primary mouse erythroid progenitors (Stadhouders et al. 2012). Further 
experiments showed characteristic features supporting enhancer activity 
(including the presence of histone acetyl transferase p300) and led to the 
conclusion that these binding sites suggest active regulatory elements in 
erythroid progenitors. The group also showed that the ACH destabilises and MYB 
expression decreases on erythroid differentiation in mouse erythroleukaemic 
(MEL) cells.  
Previous studies have shown that MYB expression is regulated via transcription 
elongation through an attenuation site in intron 1 of the gene (Bender et al. 
1987) and Stadhouders et al. showed this region interacts with the regulatory 
elements found in the intergenic region. 
LDB1 and KLF1 were also shown to be essential for up-regulation of MYB 
expression as expression decreased by 50% when both factors were inhibited by 
shRNA interference in MEL cells (Stadhouders et al. 2012).   
This study has provided further understanding about the function of the HBS1L-
MYB intergenic region, although further links of this region with HbF regulation 
still remain to be found.   
Earlier work showed MYB and HBS1L are down-regulated in individuals with 
elevated HbF and increased levels of MYB inhibit γ-globin gene expression while 
increased levels of HBS1L had no such effect on γ-globin expression. This 
99 
 
suggests MYB may be indirectly involved in the regulation of HbF levels (Jiang et 
al.2006). 
In a later study we found that high HbF associated SNPs correlated with high 
HBS1L expression (in erythroid cells from a panel of healthy individuals). F-cell 
levels however, were not significantly correlated with high HBS1L expression. 
When the samples from both studies were combined and adjusted for genotype 
effects, F-cell levels were again negatively correlated with HBS1L expression. 
These findings revealed that multiple factors contribute to FC trait and HBS1L 
expression. These factors include the SNPs at the 6q intergenic region but are 
not limited to these (Thein et al. 2007).  
SNPs in HMIP block 2 showing the strongest association with F-cell levels are 
associated with haematological traits (including reduced erythrocyte count) 
suggesting that the 6q intergenic region has a pleiotropic effect on 
haematopoiesis (Menzel et al. 2007).  
MYB is a critical factor in haematopoiesis; the absence of MYB, in MYB knockout 
mice, leads to death in utero from anaemia and the down-regulation of erythroid 
transcription factor GATA-1 (Mucenski et al. 1991, Lin et al. 1996). Low levels of 
MYB in primary erythroid progenitor cells of high HbF individuals are associated 
with accelerated erythroid cell maturation. It was suggested that the relatively 
low levels of MYB may contribute to the HbF levels, indirectly via the regulation 
of F cells and erythroid kinetics (Jiang et al. 2006).  
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Collectively, these results lead us to propose that the HBS1L-MYB intergenic 
region acts as a distal control element and regulates HbF levels indirectly, 









      C H A P T E R  5 
5 BCL11A & GATA-1 binding at the globin genes and 













A QTL for HbF at chromosome 2p15 was found by our group in 2007 and maps to 
a gene; BCL11A (Menzel et al. 2007). BCL11A is involved in lymphopoiesis and 
erythropoiesis and has been implicated in myeloid malignancies. More recently, 
BCL11A was demonstrated to act as a repressor of γ-globin expression (Sankaran 
et al., 2008). 
To investigate the role of BCL11A as a transcription factor, I aimed to study its 
interaction at the globin loci, GATA1 locus and the BCL11A locus itself. I did this 
again by ChIP-chip analysis using the same method as described in chapter 3. 
As GATA-1 is a key erythroid specific transcription factor, it was included in these 
ChIP-chip experiments in order to gain a better understanding of how both of 
these transcription factors influence globin regulation and to what extent they 
may overlap in function at these loci.  












5.2.1 BCL11A antibody optimisation 
Three ChIP grade BCL11A antibodies were available commercially. In order to 
determine the most appropriate antibody to use in terms of efficacy and 
reproducibility of enrichment levels, I tested three antibodies by ChIP and SYBR-
Green qPCR.  
As a positive BCL11A ChIP enrichment control, I used primers designed to the β-
globin LCR HS3 (Appendix 1, Table 11.2) a region which has previously been 
shown to be bound by BCL11A (Sankaran et al. 2008). The enrichment at this site 
for both BCL11A ChIP and normal IgG ChIP (negative control) was normalized to a 
reference sequence (NEFM) which acted as a housekeeper gene and also 
normalized to the input sample (DNA before ChIP with antibody). 
 
 
Figure 5.1: Fold enrichment of HS3 on the β-globin gene locus after ChIP by three different anti-
BCL11A antibodies (14B5 Santa Cruz, 18B12 Santa Cruz, 15E3 Abcam) and anti-mouse IgG 
antibody (Upstate) as a negative control. Values for 14B5 and 18B12 are means of at least 3 
experiments, +/- SE, except 15E3 and IgG data which are both from single experiments, but 
























Of the three antibodies tested in the BCL11A ChIP application (Figure 5.1), 
antibody 18B12 (Santa Cruz) gave the highest level of enrichment, so this 
antibody was used in all ChIP experiments for subsequent studies. 
5.2.2 BCL11A & GATA-1 binding in the α and β-globin loci 
 
 
I assessed BCL11A and GATA-1 binding throughout both the α and β globin gene 
loci. In order to assess the significance of our BCL11A and GATA-1 binding data 
and to place it in a useful context, we also analysed histone H3 acetylation (a 
mark associated with more open chromatin with enhancer/promoter activity) as 
well as RNAPII activity using an antibody which recognises both inactive and 
actively transcribing polymerase.  
I have shown all loci in their orientation as given in the USCS genome browser 
March 2006 assembly. Within the β-globin locus, BCL11A binding was observed 
at several locations: at LCR-HS1, -HS2, -HS3 and -HS7, towards the 3’ end of 
HBE1, ∼3.4 kb downstream of HBG1 and ∼1.5 kb upstream of HBD, the latter 
two of which are in agreement with previous results (Sankaran et al. 2008). 
Binding within the β-LCR was coincident with GATA-1 binding (Figure 5.2) apart 
from LCR-HS4 where GATA-1 binding alone was found. I was unable to find 
BCL11A binding in the immediate promoters of any of the globin genes (Figures 
5.2 and 5.3), which is in accord with a previous report using human erythroid 
cells (Sankaran et al. 2008).  
Binding at the proximal γ-globin promoter has previously been observed in K562 
cells using γ-globin promoter deletion constructs linked to a luciferase reporter 
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(Chen et al. 2009) implicating the presence of BCL11A protein. However, I found 
no expression of BCL11A in our K562 cells (Chapter 6, Fig. 6.1a). The absence of 
BCL11A in K562 cells would be consistent with the high level of γ-globin 
expression in K562 cells since BCL11A expression correlates inversely with γ-
globin levels. I was therefore unable to assess the role of BCL11A in this cell line. 
 
The human β-globin gene cluster is embedded in a larger cluster of olfactory 
receptor (OR) genes. Coincident BCL11A and GATA-1 binding was also seen at the 
OR52A1 gene, which is ∼75 kb downstream of HBB (Fig. 5.2). 
The RNAPII data suggests very strong transcription at the β-LCR-HS1, -3 and -4 
with the strongest activity seen at the HBB gene, as would be expected. There 
were also pronounced peaks towards the 3’ regions of HBG2 and HBG1 and HBD 
and around HBBP1. However, it is evident that there is a great deal of general 
intergenic transcription in agreement with previous studies (Gribnau et al. 2000, 
Miles et al. 2007).  
 
Histone H3 acetylation in primary erythroid cells is extremely high throughout 
the LCR with a dramatic dip at the LCR between HS5 and HS6 which is coincident 
with an LTR (Figure 5.2 black square between HS5 and HS6 marks the location of 
the LTR promoter region). Acetylation levels at the globin genes are highest in a 
region peaking around HBBP1 and then a second distinct region spanning from 
just 5’ of HBD through to the end of HBB with another dramatic drop beginning 




 Results of GATA-1 and BCL11A binding in the α-globin locus are shown in Figure 
5.3. BCL11A binding was entirely restricted to the multispecies conserved 
sequences (MCS) region of the α-globin locus, with three of the four peaks being 
completely coincident with GATA-1 signals at HS33, HS 40 and HS 48. These 
hypersensitive sites are involved in long range control of the α-globin genes in 
much the same way as the β-globin LCR controls the β-globin genes. The fourth 
BCL11A binding site, at HS46, showed no GATA-1 binding. The remaining GATA-1 
signals occurred at sites in between the ζ-globin (HBZ) and the ψα2 pseudogene 
(HBM) and at the orthologous region corresponding to the mouse HS-12 
element, hoHS-12 (De Gobbi et al. 2007). 
 
Although there is substantial overlap between BCL11A and GATA-1 signals, we 
believe that the signals reflect genuine independent binding rather than cross-
reactivity, resulting in immunoprecipitation of bound GATA-1 protein by BCL11A 
antibody. There is no evidence of cross-detection of GATA-1 using several 
commercially available BCL11A antibodies in Western blots using whole cell 
extracts. Further, several very strong GATA-1 binding sites, most notably at the 
BCL11A locus itself, showed no evidence of BCL11A signal. 
Technically, it is not possible to say whether the signals found near the globin 
genes themselves reflect true initial binding sites for BCL11A/GATA-1 or if they 




 Figure 5.2 ChIP-chip data for the β-globin locus in primary human erythroid precursor cells. Panels show acetylated H3 (AcH3), RNA Polymerase II, GATA-1 and BCL11A 
binding. Peaks represent scaled log2 ratios of input and ChIP material. All peaks were verified as significant (FDR=0) as determined by the NimbleScan software. Gene 
locations are shown at the bottom of the figure. HPFH and Corfu deletions (see discussion pg. 14 for references) are shown as thin horizontal lines at the top. Vertical 
arrows and grey bars indicate the location of HPFH-associated enhancers (E1, E2, E6 and E3), the 3’ hypersensitive site HS1, the Corfu PYR/δβ region and the hypersensitive 
sites (LCR 1–7). Short horizontal bars indicate H3 acetylation outside the immediate β-globin locus. Two triangles mark the location of large LINE repeats. A square between 




Figure 5.3 ChIP-chip data for the α-globin locus in primary human erythroid precursor cells. Vertical grey bars indicate Multiple Conserved Sites (MCS) upstream of the α-
globin genes; HS-48, 46, 40 and 33. hoHS-12 indicates the orthologous region corresponding to the mouse HS-12 element (De Gobbi et al. 2007). Gene locations are 




5.2.3 Differential binding of BCL11A and GATA-1 in BCL11A, GATA1 and 
HMIP  
 
Given the strong correlation between GATA-1 and BCL11A binding locations, I 
decided to investigate differential binding on these two genes themselves. I 
looked at the BCL11A gene itself for both GATA-1 and BCL11A binding activity, as 
well as for acetylated H3 and RNA polymerase II. We see an unusually large 
amount of H3 acetylation across the whole of BCL11A, in contrast to the 
neighbouring genes, where only restricted signals were seen (Figure 5.4 A).  
 
Within BCL11A, it is clear that the acetylation pattern appears in two peaks; the 
first coincides with the promoter region and the second with intron 2. RNA 
polymerase II binding is also very pronounced (Figure 5.4 A), as would be 
expected from a highly expressed gene. The RNAPII antibody recognises both the 
active and stalled polymerase complex, but in highly expressed genes, we usually 
see an accumulation towards the 3’ end of the gene as found in previous studies 
(Wahlberg et al 2009) and, once again, we see a peak of binding in intron 2.  
 
GATA-1 binding is clearly observed not only at the promoter of BCL11A, but also 
in intron 2 (Figs. 5.4 A & B), which also coincides with conserved GATA-1 binding 
motifs (Fig 5.4 B, black dots mark location of conserved GATA-1 sites). ChIP 
analysis for BCL11A binding showed no activity in or around the BCL11A locus, 
which therefore makes auto-regulation unlikely. 
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 Figure 5.4 ChIP-chip data for the BCL11A region in primary human erythroid precursor cells. (A) Genes are marked with arrows at the bottom of the figure. The 
intron/exon structure of BCL11A is specifically indicated by vertical bars. The raised HbF-associated region in intron 2 of BCL11A is indicated by a horizontal bar above the 
gene. (B) A detailed view of the BCL11A gene. Conserved GATA-1 sites (•). Three SNPs are shown, which represent the strongest raised HbF-associated QTL signals found to 




Several regions in and around the GATA1 locus showed binding of GATA-1 
including the two conserved GATA-1 sites in its promoter (marked by black dots 
in Figure 5.5). One site is the previously identified positive auto-regulatory 
promoter sequence which contains a double GATA motif ∼700 bp upstream of 
the first exon (Nicolis et al. 1991, Tsai et al. 1991). Interestingly, the only binding 
of BCL11A in the entire region was at this same regulatory site. 
 
BCL11A binding in the 6q23 locus was quite extensive throughout the genes and 
intergenic region (Figure 5.6). Binding sites were seen at the MYB and HBS1L 
promoters and coding regions of the genes. Strong binding signal was observed 
in the HMIP block 2 and most BCL11A binding sites were in coincidence with 















       
 
Figure 5.5 ChIP-chip analysis of BCL11A and GATA-1 binding at the GATA1 locus in primary human erythroid precursor cells. The gene location is indicated below 






Figure 5.6 ChIP-chip data for the HMIP region on chromosome 6q23 in primary human erythroid precursor cells. Tracks show AcH3, RNA polymerase II, GATA-1 and 
BCL11A binding. Red peaks represent binding, black horizontal arrows at the bottom indicate gene location; HBS1L and the MYB gene including the intergenic region 
between the genes. HMIP blocks 1-3 are shown by brackets above the tracks, DNase I hypersensitive sites are represented by broken arrows, and the black dots at the 




I provide here a survey of BCL11A binding in the α- and β-globin, GATA1 and 
BCL11A loci.  I observed strong BCL11A binding, in the β-globin locus particularly 
at sites previously associated with raised HbF conditions. Amongst the β-globin 
genes themselves, BCL11A/GATA1 binding was seen ∼3.3 kb downstream of 
HBG1 where deletions are known to cause HPFH (W. G. Wood, 2001).  
I also found binding of BCL11A ∼2 kb upstream of HBD. This area, which is 
deleted in Corfu δβ thalassemia, is associated with high HbF levels, and is 
thought to be involved in disruption of γ-globin gene silencing (Wainscoat et al. 
1985, Chakalova et al. 2005). It was suggested that this region, which contains an 
active transcription start site, marks the boundary of increasing transcription 
moving towards HBB (Gribnau et al. 2000, Miles et al. 2007). This is supported by 
our data which shows a pattern of increasing H3 acetylation moving towards 
HBB. Strong GATA-1 binding is also found in the promoter and 5'UTR regions of 
HBD. More recently the region 5’ of the δ-globin gene, where we find BCL11A 
signal, has been elucidated as a region necessary for γ-globin gene silencing 
(Sankaran et al. 2011). 
We also find increased levels of erythroid-specific H3 acetylation outside the β 
locus (black horizontal bars on Figure 5.2) centred around the olfactory receptor 
genes, indicative of regulatory activity. The OR51B6 gene region has been shown, 
by association studies, to contain a possible novel HbF regulator region (Solovieff 
et al. 2010), although this finding has not been replicated. Interestingly, the 
BCL11A/GATA-1 binding seen at the OR52A1 gene, ∼75 kb 3’ of HBB, is a known 
3’ enhancer region which was originally discovered via the HPFH-1 deletion 
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(Feingold & Forget 1989, Katsantoni et al. 2003). The HPFH deletions and their 
associated enhancer elements are shown in Figure 5.2. The HPFH-2, 3 and 6 
enhancers showed no GATA-1 or BCL11A binding.  
There were striking BCL11A ChIP signals at the α-globin locus (Figure 5.3), with 
strong BCL11A/GATA1 binding observed at the human multispecies conserved 
sequences (MCS) which correspond to four DNaseI hypersensitive sites (HS-48, 
HS-40, HS-33, HS-10) (Hughes et al. 2005) but again, there was no BCL11A 
binding in any immediate promoter regions. It has recently been shown that 
chromosome looping at the human α-globin locus is mediated via HS-40, 
confirming its role as the major enhancer of α-globin gene expression 
(Vernimmen et al. 2009). The importance of the other elements is not yet clear. 
However, they have all been shown to bind GATA-1 as part of a pentameric 
erythroid complex (De Gobbi et al. 2007). The fact that BCL11A binds at both α 
and β regulatory regions might be evidence of co-regulation of the α and β 
globins for maintenance of a balanced expression.  
It would appear from my results that BCL11A is not always required for GATA-1 
binding, as shown by some GATA-1 signals without BCL11A binding. To 
understand this will require experimental approaches similar to ones used to 
demonstrate that FOG-1 interaction with GATA-1 is required for GATA-1 
occupancy at select sites, such as HS2, but is not required at others, for example 
at the β globin HS3 site and at the GATA-1 target gene KLF1 (Letting et al. 2004.  
Co-immunoprecipitation experiments in erythroid cells have shown that BCL11A 
is associated with known components of the repressive NuRD chromatin-
remodelling complex, along with GATA-1 (Sankaran et al. 2008). Previously, 
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binding of a GATA-1/FOG-1/NuRD complex has been shown to silence 
hematopoietic genes (Rodriguez et al. 2005, Harju-Baker et al. 2008). I also 
observed BCL11A binding in the absence of GATA-1. Given that BCL11A is 
expressed widely, including cells which do not express GATA-1, it is assumed that 
such binding of BCL11A may be related to its other functions (Liu et al. 2006). 
NuRD has also been shown to interact with other transcription factors with 
repressive activities, for example Ikaros (IKZF1) (Kim et al. 1999, Georgopoulos et 
al. 1994) which is required for normal T- and B-cell development, an interesting 
parallel with BCL11A, which is essential for normal lymphoid development (Liu et 
al. 2003). IKZF1-null mice carrying the human β-globin locus show delayed 
switching between human γ- and β-globin (Lopez et al. 2002). A pyrimidine-rich 
region, also known as the PYR element (Figure 5.2), upstream of δ globin, was 
identified as a target for an IKZF1-containing chromatin-remodelling complex and 
was found to be involved in γ- to β-globin switching. It contained both activator 
(SWI/SNF) and NuRD repressor components (O’Neill et al. 1999 & 2000). 
 This region is removed in the Corfu δβ thalassemia deletion and, if deleted in 
transgenic mice, results in a delayed γ to β switching. IKZF1 has recently been 
shown to interact with GATA-1 as part of a γ-globin gene silencing NuRD complex 
(Bottardi et al. 2009). My discovery of BCL11A binding at the Corfu deletion site, 
between the δβ transcription start site and the PYR element, could indicate that 
it may also be part of a repressive NuRD complex in adult erythroid cells.  
Our results for AcH3 and RNAPII activity and GATA-1 binding in the BCL11A locus, 
all point towards a potentially important regulatory region in intron 2 coincident 
with previous genetic studies which identified the same region as highly 
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associated with HbF production (Menzel et al. 2007, Lettre et al. 2008, Uda et al. 
2008, Sedgewick et al. 2008). The mechanism as to how this sequence regulates 
BCL11A expression remains to be determined, but this region could be a useful 
site of investigation for the manipulation of BCL11A levels for therapeutic 
reactivation of HbF.  
 
BCL11A showed no binding to its own gene but strong signals were observed in 
the GATA1 gene. GATA1 has been shown to undergo positive auto-regulation via 
a paired GATA-1 motif in its promoter (Nicolis et al. 1991, Tsai et al 1991). I 
confirmed GATA-1 binding at this site but also show co-localised BCL11A binding. 
No BCL11A binding was found at any other point within the immediate region. 
Although BCL11A is thought to be part of a repressor complex, this GATA-
1/BCL11A co-localisation might be evidence of a distinct activator complex. 
Alternatively, there might be competition between a BCL11A repressor complex 
and a GATA-1-containing activator complex which curbs GATA1 positive auto-
regulation. This activator-complex theory could also be true for the HMIP 
intergenic region where we see a lot of BCL11A and GATA-1 binding in unison. 
 
I have been able to provide further evidence that BCL11A is involved in the 
transcriptional regulation of α- and β-globins and may also regulate and be 
regulated by GATA-1 as part of a distinct activator or repressor protein complex, 
in a way similar to that of FOG-1 and IKZF1. Moreover, I have shown for the first 
time that intron 2 of BCL11A, an area highly associated with HbF is particularly 
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KLF1 was first discovered as a protein specific to erythroid cells. The CACCC 
sequence to which it binds is found in the enhancers and promoters of many 
erythroid specific genes, most notably the β-globin gene promoter (Miller & 
Bieker, 1993).  Studies that followed its discovery revealed that KLF1 binds to this 
promoter with greater affinity than to any other promoter (Donze et al. 1995).  
KLF1 also has a direct role in activating hypersensitive site 3 in the β-globin LCR 
(Tewari et al. 1998, Gilemans et al. 1998) and studies in KLF1-/- human β-locus 
transgenic mice showed a complete lack of β-globin gene expression (Wijgerde 
et al. 1996).  These findings suggested that KLF1 has an important role in the 
globin switch.  
More recently, KLF1 has been found to have a direct role in BCL11A activation, 
through variable HbF levels detected in families with KLF1 mutations who were 
subsequently found to have altered BCL11A expression (Borg et al. 2010 Zhou et 
al. 2010). 
To further understand the regulation of the BCL11A gene I wanted to investigate 
the role of KLF1 at this locus in a more extensive way. I performed ChIP-chip 
experiments using an anti-KLF1 antibody, in the same way as I investigated 








6.2.1 KLF1 at the BCL11A locus 
 
At the time of undertaking these experiments, there were no commercially 
available ChIP grade anti-KLF1 antibodies available. ChIP tested anti-KLF1 
antibody (FRACT 5) was kindly donated by Dr. Sjaak Philipsen from the Erasmus 
Medical Centre, Netherlands. The same antibody had been used successfully in 
studies by the Philipsen group (Borg et al. 2010). 
Chromatin from primary human erythroid cells was immunoprecipitated with 
anti-KLF1 (test) and anti-IgG (negative control) antibodies and the attached DNA 
extracted, purified and tested. The HBB promoter is a known KLF1 target and so 
primers specific to this site were used in the qPCR assays to assess the efficiency 
of the ChIP experiment by measuring enrichment of this positive control site.   
 
 
Figure 6.1 Fold enrichment of the HBB promoter, a positive control site for KLF1 binding. 
Expression was measured in material immunoprecipitated with KLF1 and normal IgG as a 




























                  
Figure 6.2 ChIP-chip data on the BCL11A locus in erythroid precursor cells. Showing GATA-1, acetylated-H3 (AcH3) and RNA polymerase II (Pol II), and KLF1 binding (duplicate 
ChIP-chip experiments). Red peaks represent binding; black horizontal arrow below peaks indicates gene location. The track below this indicates promoter associated signal in the 
area. The black vertical arrows indicate consistent and reproducible binding sites for GATA1 and KLF1. Black dots above the first track indicate a cluster of 4 strong AcH3 signals at 





















KLF1 binding was found at the BCL11A locus, mostly restricted to the gene itself. 
The strongest and most consistent peaks were at exon/intron 1 of the gene which 
coincides with the promoter associated signal from the ENCODE database, 
strengthening the accuracy of my ChIP-chip data. The second strongest peak was 
found at exon 4. 
 Some signal was found at the critical intron 2 interval, but this was not 
reproducible in the second independent ChIP-chip experiment and therefore we 
considered it less important than the other two stronger and more consistent 
signals (marked out by arrows on the KLF1 track in Figure 6.2).  
In figure 6.2 I also included ChIP-chip data for AcH3, RNA Polymerase II and GATA-1 
at the BCL11A locus (which was previously identified in chapter 4) in combination 
with the KLF1 data to put in context of general transcriptional activity at the locus. 
AcH3 and RNA Pol II was seen within the gene and abundantly in intron 2, close to 
the high scoring SNPs, and also where I found strong GATA-1 binding. 
To validate the data obtained from the ChIP-chip experiments I repeated ChIP with 
the same anti-KLF1 antibody in human erythroid precursor cells and measured the 
enrichment of the most consistent sites by SYBR-Green qPCR using primers 








                  
                    
     
 
 
Figure 6.3 a) Fold enrichment of two of the consistent KLF1 sites on the BCL11A locus (labelled 1 
and 2) after ChIP with anti-KLF1 antibody (FRACT 5, Dr. Sjaak Philipsen’s laboratory, Erasmus, 
Netherlands) and NEFM housekeeper gene as a negative control and normalizer. Enrichment 
determined by SYBR-Green qPCR and analysed by normalizing to NEFM housekeeper gene. Values 
are mean fold enrichment of at least 3 PCR reactions. b) Corresponding KLF1 binding sites on the 
BCL11A locus found by ChIP-chip and measured for enrichment shown in a). 
 
Both sites showed more than 10 fold enrichment when normalised to the 
housekeeping gene (NEFM), which also acted as the negative control. This result 
confirmed that the signals calculated from the ChIP-chip experiments are true 





















6.2.2 KLF1 at the α- and β-globin locus 
The β-globin gene (HBB) promoter contains a CACCC sequence which is a binding 
motif for KLF1. I decided to measure KLF1 activity at the β-globin locus because a) I 
wanted to measure KLF1 binding at a known binding site (the HBB promoter) to test 
the efficiency of the ChIP-chip experiments, and b) I wanted to see a more 
extensive view of KLF1 binding at the locus and nearby LCR. 
So far there is very little literature on the role of KLF1 at other erythroid specific 
genes other than the HBB gene.  Therefore, in addition I decided to assess KLF1 







 Figure 6.4 KLF1 and GATA-1 binding in the β-globin gene locus on chromosome 11 in primary human erythroid precursor cells by ChIP-on-chip analysis. Red peaks represent 
binding; black horizontal arrows below tracks indicate gene location. The hypersensitive sites of the β-LCR are marked by black vertical arrows above the tracks. The final track 






Figure 6.5 KLF1 and GATA-1 binding in the α-globin locus on chromosome 16 in primary human erythroid precursor cells by ChIP-on-chip analysis. Red peaks represent binding; 
black horizontal arrows below the tracks indicate gene location. The hypersensitive sites; HS-48, 46, 40 and 33, including the orthologous mouse hoHS-12 element are marked by 





Figure 6.6 a) Fold enrichment of KLF1 binding sites 1 and 2 as indicated in figure 6.4. Enrichment 
was measured by SYBR-green qPCR using specific primers. The HBB promoter served as a positive 
control. All values were normalized to the NEFM housekeeping gene which was also used as a 
negative control for enrichment. Values are mean fold enrichment of at least 3 PCR reactions. b) 
Corresponding KLF1 binding sites on the β-globin locus found by ChIP-chip and measured for 
enrichment as shown in a). 
 
I viewed GATA-1 with KLF1 binding signal at the β-globin locus (Figure 6.4). As 
expected, I found KLF1 binding at the HBB promoter, a known KLF-1 target (Miller & 
Bieker 1993). In addition, two strong KLF1 signals are seen at the β-globin LCR, one 
of which was at HS3. These KLF1 binding sites also coincide with GATA-1 binding 
sites at the LCR, where there is also considerable enhancer/promoter activity as 





















Another KLF-1 binding signal was found between HBBP and HBG1 where another 
GATA-1 binding site is also found. 
I proceeded to confirm the findings by repeating ChIP of primary human erythroid 
cells with the same anti-KLF1 antibody followed by SYBR-green qPCR. To check 
enrichment as a positive control, primers were designed to peak 1 found at the HBB 
promoter (Figure 6.4) and peak 2 in the β-LCR (HS3). As a further check, I measured 
enrichment of the HBB promoter using previously published primers, designed 
specifically for the KLF1 CACCC sequence (Figure 6.6). This site is a direct target of 
KLF1, and had been used as a positive control for KLF1 in earlier ChIP experiments 
(Figure 6.1). NEFM was used as the normalizer and negative control. 
Significant KLF1 binding sites were also found in the α-globin gene cluster and some 
discrete sites at the hypersensitive sites which are involved in long-range control of 
the α-globin genes (Figure 6.5). KLF1 signal between HBZ and HBM is in coincidence 
with GATA-1 signal as well as high levels of AcH3 and RNA Pol II at this region 
(Figure 5.3 for AcH3 and Pol II data). KLF1 also occupies sites at the HBM gene and 
promoter, with further signal detected at the HBQ1 gene and downstream of this 
gene. The KLF1 binding sites found at the regulatory element of the locus marked 
by hypersensitive sites appears at HS48, 46 and around HS33, which are also 
occupied by GATA-1. AcH3 and RNA Pol II activity is also particularly high at the 




6.2.3 KLF1 at the HMIP locus 
Earlier I described GATA-1 binding in the HMIP region which is strongly associated 
with F-cell levels. I now measured KLF1 binding in this region to investigate the role 
of KLF1 in the intergenic region and on the MYB and HBS1L genes. 
I found very little KLF1 binding in this region (Figure 6.7). Some signal was found at 
the HBS1L promoter which coincides with GATA-1 and BCL11A signal. Stronger 
signal was found at the MYB gene promoter which was in coincidence with BCL11A 
and a further signal was also seen within the MYB gene itself.  
Apart from one binding signal near the 5’ end of HBS1L, no KLF1 signal was found in 




 Figure 6.7 KLF1, BCL11A and GATA-1 binding at the 6q23 HMIP locus in primary human erythroid precursor cells by ChIP-on-chip analysis. Red peaks 
represent binding, black horizontal arrows at the bottom indicate gene location; HBS1L and the MYB gene including the intergenic region between the genes. 
HMIP blocks 1-3 are shown by brackets above the tracks, DNase I hypersensitive sites are represented by broken arrows, and the blue dots at the bottom mark 






KLF1 signal at BCL11A suggests that KLF1 has a regulatory role on the gene. 
Binding is found to be strongest at intron/exon 1 which is a possible enhancer of 
the gene as indicated by acetylated-histone H3 in this area (Figure 6.2). Strong 
binding is also seen at exon 4; which is the XL/L isoform specific exon and 
evidence suggests that the large isoforms are most abundantly expressed in 
primary adult human erythroid cells (Sankaran, 2008). KLF1 signal at this 
particular exon suggests that KLF1 may be involved in regulating transcription of 
specific BCL11A isoforms.  
KLF1 binding is also seen at the HBB promoter consistent with other studies 
(Zhou et al. 2010). KLF1 signal seen in the β-LCR demonstrates the regulatory 
role of KLF1 on the β-globin gene. I found that KLF1 binds to the two regions of 
the β-globin locus as does BCL11A (see Chapter 5, Figure 5.2). In fact, BCL11A, 
GATA-1 and KLF1 binding coincides at these two positions; between the HBG1 
and HBBP genes, a site where deletions are known to cause HPFH (Bank 2006).  
Binding also coincides in the LCR at HS3 which is part of the regulatory element 
of the locus which is responsible for activation of the downstream β-globin 
genes.  
It has already been suggested that BCL11A and GATA-1 may be working together 
in a NuRD complex (Chapter 5.3). Considering the KLF1 binding signals in 
coincidence with BCL11A and GATA-1, it is possible KLF1 may also be part of the 
same transcription repressing NuRD complex. This complements the latest model 
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of β-globin gene control suggesting KLF1 regulates BCL11A, resulting in the 
repression of γ-globin.  
KLF-1 signal also coincides with GATA-1 signal at the α-globin locus within the 
gene cluster as well as the 5’ regulatory elements of the locus, showing a more 
global role of KLF-1 within the globin genes (Figure 6.5). 
KLF-1 may have an effect on the MYB gene at the 6q locus (Figure 6.7) as I found 
binding signals at the MYB gene promoter, but seems to show no interaction in 
the intergenic region. 
Soon after our findings, others showed, through mouse studies, that KLF1 binds 
to a -81kb enhancer which contains a conserved CACCC-box motif, upstream of 
the MYB transcription start site on the HBS1L-MYB locus and is believed to 
activate MYB transcription (Stadhouders et al. 2011). However, I did not observe 
this binding site in my KLF1 ChIP-chip data in human erythroid precursor cells. 
Other transcription factors have been shown to regulate MYB expression 
including GATA-1, Ets-1 and MYB itself (Bartunek et al. 2003, Sullivan et al. 1997, 
Nicolaides et al. 1991). It is possible that KLF-1 is another transcription factor 
that contributes to the overall expression of MYB. 
Studies have shown that MYB introns contain regulatory sequences which are an 
important part of MYB control (Bender et al. 1987) which include enhancer 
elements in intron 1 and 4 (Dooley et al. 1996, Seib et al. 1994).  
KLF1 is a critical regulator of globin gene expression and my research so far 
supports this role.  The KLF1 binding profile presented in this chapter however, is 
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limited to primary human erythroid precursor cells and this binding activity may 
be erythroid specific. KLF1 ChIP experiments in other cell types or cell lines would 
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      C H A P T E R  7 
7 A study of BCL11A isoforms in erythroid cells and 












A QTL on the BCL11A gene accounts for 15% of the variance in HbF levels in the 
healthy European population (Menzel 2007). Since the discovery of this QTL, 
much work has been undertaken to elucidate its role in HbF regulation and the 
globin switch. BCL11A was initially isolated by retro-viral tagging studies to 
identify leukaemia disease genes in mice (Nakamura et al. 1996). 10 years prior 
to these findings, two rare cases for chronic lymphocytic leukaemia were studied 
by Fell et al. (1986) and were found to have a chromosomal translocation 
involving part of what we now know as the BCL11A gene [t(2;14)(p13;q32)].  
Until the identification of BCL11A as a QTL for HbF control, it was not even 
known to be expressed in erythroid cells. In a more recent study, raised 
expression levels of BCL11A were detected in some JMML cases and a subset of 
AML patients with monosomy 7 (MO7) with poor disease outcome. Monosomy 7 
is also a common feature of JMML (Yin et al. 2008). 
BCL11A exists as 3 major isoforms; XL, L and S. The distribution, function and 
purpose of these isoforms is as yet unclear. We wanted to identify which 
isoform(s) is present in erythroid cells and if the same or different isoform(s) is 
present in myeloid leukaemia cells, as this would give an indication as to the 








Figure 7.1 Representation of the BCL11A gene. Horizontal blue bars indicate the cross-exon 
design of amplicons to include exons specific to each isoform (XL, L, S) and all isoforms. 
 
First, we over-expressed each isoform in K562 cells as positive controls for 




7.2.1 Over-Expression of BCL11A isoforms in pEF6 vector 
Erythroid cDNA was used to amplify cDNA corresponding to the three main 
isoforms of BCL11A. Even though there is very little of the L or S forms in 
erythroid cells, it was evident that sufficient mRNA was produced to make RT-
PCR possible. Proof-reading polymerase (Velocity Taq, Bioline, UK) was used to 
reduce the possibility of polymerase-induced mutations. 
The RT-PCR primers used contained restriction sites BamHI and NotI (Appendix 2, 
Figure 11.2) to enable the in-frame cloning of the cDNA into the expression 
vector pEF6 (Invitrogen, UK) (Figure 7.2). This vector contains a highly active E1α 
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promoter, which would ensure expression in K562 cells, even though this cell 
type does not normally express BCL11A at any great level. 
 
Figure 7.2. The pEF6/V5-His over-expression vector used to over-express the BCL11A isoforms. 
The V5 and His-tag linkers were not required and were therefore not designed to be added to the 
expressed BCL11A protein. This was achieved by leaving the naturally occurring BCL11A isoform 
stop codons intact. 
 
Following digestion of the RT-PCR products with BamHI and NotI to allow sticky 
end cloning, it proved impossible to successfully clone the amplicons directly into 
BamHI - NotI digested pEF6. The reason for this was not clear, but was likely due 
to inefficient digestion of the PCR ends or degradation of the ends. It was 
therefore decided to clone the products into a TOPO vector first, sequence to 
verify products, digest with BamHI and NotI and then clone into pEF6. The TOPO 
vector chosen was the TA-cloning vector TOPO 2.1 (Invitrogen, UK). RT-PCR 
products were gel-purified and A-tailed. The PCR products were then cloned into 
the TOPO vector according to the manufacturer’s instructions. Several mini-
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preps were prepared for each TOPO construct which were then sequenced to 
assess PCR fidelity. 
Once sequence integrity was established, selected TOPO clones were digested 
with BamHI and NotI to release their coding inserts, which were then isolated by 
gel purification. The pEF6 vector was opened with the same enzymes, 
dephosphorylated and the cDNA PCR fragment cloned in using the Rapid Ligation 
Kit (Roche, UK), according to the manufacturer’s instructions. The resulting 
bacterial clones were screened by miniprep and inserts verified by restriction 
digest (Appendix 2, Figure 11.3). 
 
Following electroporation into K562 cells, expression was assessed after 72 
hours. RNA was extracted, reverse transcribed and TaqMan assays performed 
using a primer/probe set which would recognise all forms. Results show that high 
levels of expression were achieved for all isoforms (Figure 7.3). Protein for 





















Figure 7.3 BCL11A isoform overexpression in K562 cells including negative control (K562 cells 
transfected with empty vector). Gene expression levels were determined by Taqman qPCR using 
primer probe mix specific to BCL11A. Values are means of at least 3 experiments +/- SE. 
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Figure 7.3 displays the results of the qPCR showing that all three isoforms were 
expressed in K562 cells in comparison to the negative control (an empty pEF6 
plasmid transfected into K562 cells). This result confirmed that the transfection 
had been successful and that cDNA was being expressed from all constructs.  
 
7.2.2 BCL11A isoforms in erythroid cells 
I aimed first to identify the protein isoforms present in erythroid cells by western 
blotting, and then to measure by qPCR, the expression of the individual isoforms 
in different subsets of myeloid leukaemia. To differentiate the L from XL forms 
which are very similar in size, I isolated protein from K562 cells overexpressing 
each of the different isoforms as size markers. These were run on the same gel 
with protein extracted from erythroid cells for direct size comparison. K562 cells 
do not naturally express BCL11A which make them an appropriate cell model for 
overexpression studies. 
 
To determine which isoform is translated in primary erythroid cells, a western 
blotting time course was performed (Figure 7.4a). Protein was isolated from 
primary human erythroid progenitor cells at different time points of the culture 
in phase II from day 0 to day 10. Native K562 cells were used as a negative 
control for BCL11A, protein from K562 cells overexpressing the isoforms was 
used as a positive control and β-actin was used as a loading control. I found that 
BCL11A was expressed in primary human erythroid cells from day 4 through to 
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day 8/9 of the culture. Only one isoform was present and appeared to be one of 
the large isoforms. 
In Figure 7.4b I show both the XL and L protein isoforms are over-expressed in 
K562 cells (lanes 1&2), but I failed to see any presence of the S isoform (lane 8). 
In the same figure, a direct visual size comparison clearly shows that primary 
human erythroid cells express the XL isoform only.
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Figure 7.4 a) presence of BCL11A protein as detected by western blotting in primary human erythroid cells from Days 4, 6, 7, 8, 9 and 10 of phase II of culture (lanes 2-7). 
BCL11A antibody (14B5 sc-56011 from Santa Cruz Biotech) was used in a 1:200 dilution with 5% milk in PBST. Non-transfected K562 cells (lane 8) were used as a negative 
control for BCL11A protein expression. b) BCL11A western blot of K562 cells transfected with BCL11A L, XL and S overexpression plasmids (lanes 1,2 & 8, respectively). No 
S isoform was detected.  BCL11A protein was detected in erythroid cells from days 4 and 6 of the culture (lanes 4 and 5, respectively) and appeared to be the XL form 
when compared to protein control (L and XL, lanes 1 and 2, respectively). For both blots β-actin (AC15 from Abcam) was used as a loading control in a 1:2000 dilution with 
5% milk in PBST.










            Lane:           1     2       3      4    5      6      7    8     1       2       3      4        5       6      7      8 Lane: a) b) 
 L       XL       0      4        6       8       10      S   
BCL11A 
isoforms Erythroid cell culture days 
              
            BCL11A 
            XL~ 125kDa                                                      
            L ~  100kDa 
 
       β-actin ~ 42kDa       S ~  35kDa 
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7.2.3 BCL11A isoforms in myeloid leukaemia 
 
To investigate BCL11A isoform expression in myeloid leukaemia, cDNA samples 
were obtained from the Central England Haemato-oncology Research Biobank 
(CEHRB) with ethical approval. I received cDNA samples obtained from whole 
blood and bone marrow samples of patients with CMML, JMML, AML and AML 
with monosomy 7 and deletions within 7q (del 7q), as well as normal cDNA 
samples as the control group. BCL11A isoform expression was measured by 
SYBR-Green qPCR using primers specific to each isoform (Appendix 1, Table 
11.5).  
qPCR data displaying fold change in expression of isoforms in all patient samples 
across all disease groups is shown in Figure 7.5.  All measurements were 
normalized to HPRT (housekeeper gene) and one individual from the CMML 
group. A control group of 10 individuals (no disease) was also included, as well as 
a group of patients with AML and normal karyotype (n=10). Full sample details 
including karyotype classification is listed in Appendix 4, Tables 11.8-11.12. 
 
I also measured the isoforms in primary human erythroid progenitor cells, data 
shown in Figure 7.6. All isoforms were expressed but due to variation in primer 
efficacy and amplicon design, expression levels of different isoforms cannot be 
compared (see Discussion 7.3).
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Figure 7.5 Fold change in expression of BCL11A isoform XL, L, S and all forms, in patients with AML 
M07/(del)7q (n=30), CMML (n=10), JMML (n=6), AML with normal karyotype (n=10) and a control group 
of normal individuals (n=10). Expression was measured by qPCR using primers specific to the individual 
isoforms. All CT values were normalized to the housekeeper gene HPRT and one randomly selected 














































































                   AML MO7, (del) 7q                                Control              CMML            JMML      AML normal 
                   AML MO7, (del) 7q                             Control              CMML             JMML    AML normal 
                  AML MO7, (del) 7q                              Control                CMML            JMML      AML normal 
                       AML MO7, (del) 7q                           Control                CMML          JMML      AML normal 




    
    
    
 
Figure 7.6 Fold change in expression of the BCL11A isoforms, ‘XL’, ‘L’ and ‘S’ in primary human 
erythroid progenitor cells from phase II day 0, 3,5,6 and 7 of culture. Native K562 cells (untransfected) 
were used as a negative control for BCL11A expression. cDNA from K562 cells transfected with over-
expression plasmids for ‘XL’, ‘L’ and ‘S’ isoforms were measured as positive (and negative) controls for 
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 Figure 7.7 qPCR expression data (from Fig.7.5) was averaged for each group and displayed +/- SEM. 
Statistical significance between AML M07/(del) 7q and all other groups was measured by students t-test. 






















































Figure 7.8 qPCR expression data (from Fig.7.5) was averaged for each group minus the blood samples 
and displayed +/- SEM. Statistical significance between AML M07/(del) 7q and all other groups was 





















































7.2.4 KLF1 expression in myeloid leukaemia 
Since new studies have shown KLF1 regulates BCL11A expression, I decided to 
measure KLF1 expression in the same myeloid leukaemia groups; AML, CMML and 
JMML to see if and how KLF1 expression correlates with BCL11A expression in these 
cell types.  
KLF1 expression was not significantly different between the three disease groups 
analysed except for a few individuals with higher expression, including one from the 
JMML group with MO7 and very high expression (Figure 7.9). 
 
 
Figure 7.9 KLF1 expression in AML, CMML and JMML groups. Y axis shows fold change in 
expression. Expression was measured by qPCR using primers specific to the individual isoforms. All 
CT values were normalized to the housekeeper gene HPRT and one randomly selected sample from 
the CMML group (   ). Individual with monosomy 7(    ).                                                                                                               





































7.3.1 BCL11A in erythroid cells 
Western blotting analysis revealed BCL11A protein is highly expressed in erythroid 
cells from day 4 of culture through to day 8, after which the protein is reduced. 
Figure 7.4a clearly shows a single band at each day of culture; therefore only one 
isoform is present in these erythroid cells. When this band is measured alongside 
the XL and L isoform in figure 7.4b), it is clear that this band corresponds with the 
XL isoform (control XL overexpressing K562 cells). Therefore I conclude that only 
the XL isoform is present in erythroid cells. These findings mirrored those previously 
reported by Sankaran et al. (2008) who also found the large isoforms expressed 
exclusively in adult erythroid cells and little or no expression of the short isoform in 
these cells.  
Although we could over-express all three major isoforms of BCL11A in K562 cells 
(RNA levels detected in Figure 7.6), presence of the S isoform protein could not be 
detected in several experiments (Figure 7.4b). We have no clear explanation for 
this, but suggestions are that the S BCL11A isoform may be less stable or it could be 
transcribed but not translated in K562. Previous studies have shown that the S 
isoform is not present in definitive erythroid cells; however, the S isoform was 
detected in primitive erythroblasts, indicating that the BCL11A isoforms could be 
stage specific (Sanakaran et al 2008). It is therefore important to further 
understand the roles of the isoforms, as they may well lead to uncovering the role 




7.3.2 BCL11A in myeloid leukaemia cells 
Previous studies have shown a link between myeloid disorders, monosomy 7 and F-
cell levels (Craig et al. 1996). One study of MDS patients revealed raised F-cell levels 
in 62% of patients. Moreover, 4 MDS patients with monosomy 7 or 7q deletion had 
the highest number of F-cells (Craig et al. 1996).                          
JMML, a rare childhood form of myeloid disorder is often presented with raised 
HbF. 25-30% of JMML cases present with monosomy 7 or (del) 7q (Emanuel 2008). 
Reports have shown that elevated HbF is associated with JMML with normal 
karyotype, and in contrast, only normal to moderately elevated levels are reported 
in JMML patients with MO7 (Niemeyer et al. 1997). 
 BCL11A was found to be up-regulated in cases of AML with monosomy 7 and in 
some JMML cases (Yin et al. 2009). I obtained cDNA samples of patients with 
CMML, AML (with MO7 or -7q) and JMML. Of the groups studied, expression of 
BCL11A is highest in AML with monosomy 7 or (del) 7q, and the L and S isoforms of 
BCL11A, the most highly expressed.  
After these initial results I expanded my sample size for the AML group with MO7 or 
7q deletion to 30 samples. 10 AML samples with normal karyotypes were also 
included in the isoform expression study to see if the difference lay within 
chromosome 7 affected cases or if this was seen in normal AML cases too. A larger 
sample size confirmed the same pattern; patients with AML with MO7 or (del) 7q 
highly expressed the L and S isoforms compared to all other disease groups 
measured. This difference in expression was statistically significant (p<0.05, Figure 
7.7 and 7.8). When measuring the bone marrow samples alone from each group, 
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statistically significant difference between AML with MO7 or (del) 7q and all other 
groups remained (Figure 7.8).  
The amplification efficiency of the different isoforms is very different, and so, inter-
isoform comparison is unreliable. For this reason, I could only compare expression 
of each isoform between the different disease and control groups but not their 
relative expression within each disease or control group.  
My data shows that the XL isoform is predominant in erythroid cells and the L and S 
isoforms are highly expressed in acute myeloid leukaemia cells with M07 or other 
chromosome 7 abnormalities.  
It may be that an element on chromosome 7 plays a role in the differential 
expression of BCL11A isoforms. Chromosome 7q has been widely implicated in 
myeloid malignancies and many studies have identified genes on chromosome 7 
effected by MO7, (del) 7q or other chromosome 7 abnormalities. I carried out a 
literature search to find any common genes affected in chromosome 7 
abnormalities that may be linked to haematopoiesis or BCL11A and may help to 
explain the high levels of BCL11A.  The effected genes vary almost completely from 
study to study, probably because every patient included has a unique karyotype. A 
more precise region of chromosome 7 that could be involved with BCL11A cannot 
be pinpointed on the basis of existing data because deletions of 7q are different in 
every patient. Moreover, micro-deletion information is usually not provided in 
routine karyotyping as they are too small to detect by regular cytogenetic 
techniques and micro-deletions vary greatly. It is therefore very difficult to narrow 
down a causative region of chromosome 7.  
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In a more recent study, a SNP influencing platelet volume, count and function was 
identified on 7q (Soranzo et al. 2009), further highlighting the importance of this 
region in haematopoiesis. The significance of chromosome 7 in context of BCL11A 
regulation however is something which will need further investigation. 
No HbF measurements were made for these samples by the CEHRB and as I only 
had cDNA samples, I was unable to measure HbF levels. As a surrogate, I measured 
the γ/β globin expression ratio, but this measurement was inconclusive. This may 
be because these myeloid leukaemia samples contain mostly blast cells and very 
few red cells, therefore making it difficult to measure globin expression. 
Information on the HbF in these samples would allow correlation, if any, with the 
levels of BCL11A in these samples.  
In recent studies, KLF1 has been shown to regulate BCL11A (Borg et al. 2010, Zhou 
et al. 2010). I measured KLF1 expression in the AML MO7/-7q, CMML and JMML 
groups. Interestingly, I found very high KLF1 expression in the individual with JMML 
and MO7 (Figure 7.9), this individual also had slightly raised BCL11A in comparison 
to the rest of the group. However, this result is somewhat subtle and a real trend 
can only be confirmed with a larger sample size. 
In a study of MDS patients with MO7, looking at gene expression profiles, genes 
related to haematopoetic progenitor cell proliferation and blood cell function were 
dysregulated. Genes down-regulated in MO7 were those controlling cell growth and 
differentiation (Chen et al. 2004). It is likely that disordered erythropoiesis in MDS 
and JMML with MO7/-7q contributes to HbF expression seen in MO7 cases 
(Papayannopoulou et al. 1991). 
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I observed in the CMML group that the XL isoform was higher in samples taken 
from whole blood versus samples taken from bone marrow (Figure 7.5). This may 
be because the whole blood samples are likely to contain more mature erythroid 
cells, which may contribute to higher XL expression observed in these samples. 
When all bone marrow samples were averaged (i.e. excluding the blood samples), I 
found a statistically significant difference in the expression of the XL isoform 
between the group AML with MO7 or (del) 7q and CMML, JMML and control groups 
(Figure 7.8). 
In conclusion, the results presented in this chapter further our understanding of the 
BCL11A isoforms. I demonstrate here that the XL isoform is predominantly 
expressed in human primary erythroid progenitor cells and it is likely that an 
element linked to chromosome 7 has a regulatory effect on the expression of 
BCL11A, as seen through raised levels in AML samples with MO7/-7q.  
A more in-depth study is warranted, which might reveal regulatory elements on 
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8 Analysis of SNPs in BCL11A intron 2 in twins with 












The strongest HbF-associated SNPs (key SNPs) are found in intron 2 of BCL11A 
(Figure 8.1). Data suggests that the region contains important regulatory 
sequences, as indicated by the GATA-1 erythroid transcription factor binding 
patterns at this region. It is not clear, however, how the region regulates the 
BCL11A gene, the expression of which influences γ-globin expression. 
HbF-promoting variants (alleles) of these SNPs are in strong linkage disequilibrium 
(‘high HbF haplotypes’). HbF-lowering alleles, on the other hand exist together in 
linkage disequilibrium as ‘low HbF haplotypes’. 
I decided to further analyse typical high HbF and low HbF haplotypes in this region 
to either confirm that all SNPs are known or to identify any novel sequence variants 
that might characterise these haplotypes. This would inform us if the known SNPs 
are in fact the only candidates for causative sequence variants effecting F-cell 
levels. Alternatively, there may be new, previously unknown SNPs which may 
individually or collectively contribute to the trait. 
We re-sequenced 20kb of intron 2 (the critical region containing strongest-
associated SNPs- Table 8.1) in five individuals with extreme F-cell levels who were 
homozygous for representative high HbF and low HbF haplotypes, from the St. 
Thomas’ UK Adult Twin Registry (www.twinsuk.ac.uk).  These subjects had 
previously been genotyped during the first GWAS that identified BCL11A as a QTL 
for HbF (Menzel et al. 2007). These individuals were homozygous for the four key 
SNPs associated with F-cell levels found through several GWAS; rs1123573, 
rs6732518, rs6545816, rs766432. Further SNP haplotypes could therefore be 
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inferred directly. Of the five individuals studied, three had very high F-cells and 
carried two copies of the high HbF haplotype each. Two subjects had very low HbF 
values and carried two copies of the low HbF haplotype each (Table 8.2).  
Following re-sequencing work we wanted to know if the different SNP alleles 
caused differences in near-by transcription factor binding sites (TFBS). We carried 
out some basic bioinformatics analysis of transcription factor binding sites in the 
presence of the different SNP alleles for each of the high scoring SNPs.  
We attempted to further analyse the nature of the intron 2 QTL region as a putative 
enhancer of the gene and designed reporter assays to explore this possibility in 
both high and low HbF individuals. From the re-sequencing results at the HbF 
BCL11A QTL, we found no new sequence variants in the region which could account 
for the raised HbF. Therefore we conclude that one or more of the known SNPs are 
responsible for the functional mechanism which could lead to the raised HbF 
phenotype in this group. One suggestion is that the QTL acts as an 
enhancer/regulator of BCL11A expression. In an attempt to understand how these 
SNPs, singly or in combination, might regulate the expression of BCL11A, and in 
turn, how they might affect HbF levels, we tested the function of the QTL SNPs 
using an enhancer assay based on a luciferase reporter system. 
Primers were designed to amplify 2 large sections of the QTL containing the high-
scoring SNPs and the novel GATA-1 binding sites (Figure 8.1). DNA from the same 
raised and low HbF genotype/phenotype individuals were used and compared in 
the luciferase assay. 
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 Figure 8.1 Schematic of BCL11A on chromosome 2. A) The first track shows GATA-1 binding signals in intron 2 (red peaks); black horizontal line represents gene, 
vertical lines mark exons. Vertical black lines below the gene mark location of key SNPs in the region. B) A detailed view of the intron 2 region; co-ordinates 
chr2:60,560,000-60,580,000 (20 kb). Black horizontal line indicates intron 2 of the gene, key SNPs are marked out with black vertical lines below this. The pale blue 
horizontal lines below the figure indicate the design of sequencing amplicons of c.5 kb each, spanning the 20kb region (Amplicon 1-4).
A 
B 
Amplicon 1 Amplicon 2 Amplicon 3 Amplicon 4 
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Table 8.1 Strongest HbF-associated SNPs found to date, including details of GWAS and populations 
in which they have been identified. * SNPs with highest association and located near the GATA-1 
binding sites in intron 2 of BCL11A. 
 
SNP GWAS and populations 
rs1123573 Menzel et al. 2007 (N.European) 
rs6732518 Menzel et al. 2007 (N.European) 
rs6545816 Menzel et al. 2007 (N.European)                                                        
Sedgewick et al. 2008 (Thai) 
rs1427407 Menzel et al. 2007 (N.European) 
rs766432* Menzel et al. 2007 (N.European)                                                        
Sedgewick et al. 2008 (Chinese w. β-thal, Thai w. β-thal major, 
African American w. SCD) 
rs11886868* Menzel et al. 2007 (N.European)                                                        
Uda et al. 2008 (Sardinian, w. β-thal, w. SCD) 
rs4671393* Menzel et al. 2007 (N.European)                                                        




Table 8.2 SNP haplotypes that occur more frequently in either high F or low F phenotypes. Patient 
IDs are divided into high F and low F with IDs listed in the second column from the left.  
 
 
  SNP haplotypes 
 
Patient 




F 1411 A C A C 
1440 A C A C 
3180 A C A C 





2109 G T C A 




8.2.1 Re-sequencing in extreme trait twins 
The critical 20kb region of intron 2 was sequenced in 4 segments of around 5kb 
each (Figure 8.1). These segments were amplified using overlapping primers 
(Appendix 1, Table 11.4) and proof-reading polymerase, Velocity (Bioline, UK). The 
advantage of using a proof-reading polymerase is that it amplifies the exact same 
sequence as the template including mutations and SNPs, with few or no errors.  
Once the large segments of the intron 2 region were amplified in all 5 individuals, 
the DNA was run on a 0.8% agarose gel and visualised. After confirmation of the 
amplified product, the bands were excised from the gel, column purified and 
sequenced directly (protocol in chapter 2.6.1).  
The sequencing data was analysed using the Sequencher programme and 
assembled to the 20kb reference sequence (version, Mar.2006 (NCBI36/hg18)), 
accessed through the UCSC genome browser (http://genome.ucsc.edu/cgi-
bin/hgGateway).  
I designed sequencing primers tiling the length of each large amplicon with an 
overlap of about 100bp for complete coverage of the region. 
The sequence was assembled for each individual against the template, 52 SNPs 
were identified and confirmed (Figure 8.2), of which 4 SNPs represented the “high” 
and “low” HbF haplotypes. However, no new sequence variants were identified in 






Figure 8.2 Sequencing data from extreme trait twins in the high scoring region of intron 2 (chr2:60,560,000-60,580,000). The figure displays key SNPs (pink box- high F 
samples are highlighted in peach and low F samples are highlighted in pale blue) as well as all other SNPs found in the region. Sample ID and HbF phenotype is listed in the 
first two columns to the left; the first row from the top displays SNP ID, SNP position co-ordinates in the genome (UCSC genome browsers, v. March 2006 NCBI36/hg18, 
http://genome.ucsc.edu/cgi-bin/hgGateway?hgsid=299726899&clade=mammal&org=Human&db=hg18) are marked vertically in red below the SNPs. Red blocks below the 
SNP co-ordinates represent the location of GATA-1 binding sites, orange blocks represent weaker binding sites.
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 8.2.2 In- silico transcription factor binding analysis in extreme trait twins 
 
Transcription factors (TF) have a key role in gene regulation (Cantor & Orkin, 2001) 
and erythroid development is largely mediated by many transcription factor 
complexes and cofactors, cis- or trans-acting to the expressed gene (Soler et al. 
2010, Stadhouders et al. 2012). Any disruption or alteration in the binding sites of 
these important TFs can affect the expression of their target genes. It is possible 
that SNPs found in association with extreme HbF levels cause such an alteration in 
the binding of factors which contributes to the aberrant expression of HbF, 
indirectly via genes that influence HbF production. To investigate this we carried 
out a bioinformatics transcription factor binding analysis on the SNPs in both sets of 
individuals to assess if there were any differences in transcription factor binding as 
a result of the sequence variants. 
We used an online programme called Transcription Element Search System (TESS) 
(http://www.cbil.upenn.edu/cgi-bin/tess) to predict TF binding sites at our specific 
sequences. TESS identifies binding sites using site or consensus sequences and 
positional weight matrices from the TRANSFAC database (database of eukaryotic 
transcription factors, their genomic binding sites and their DNA binding profiles).By 
inputting the different SNP alleles and including 25bp sequence either side of the 
SNP, we generated a transcription factor binding site map and compared this for 
each SNP between the high and low HbF samples (Figure 8.3-8.6). 
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Some differences in transcription factor binding were seen between the two alleles 
for each SNP. The high HbF associated ‘T’ allele of rs1427407 showed binding sites 
for YY1, a repressor and activator of promoters which is also involved in histone 
modification. The low HbF associated ‘G’ allele showed binding sites for LEF1, which 
is known to bind to the T-cell receptor- alpha enhancer, maximising enhancer 
activity. A c-Myb binding site is also located near this SNP, which is unaltered 
between the extreme traits. The ‘A’ allele of rs766432 is associated with low HbF 
and analysis revealed two transcription factors binding sites for TBP and TF11A, 
both of which are involved in positioning and assembly of RNA polymerase II. 
A binding site for Nf1 (negative regulator of the RAS signalling pathway) was found 
near the high HbF associated ‘C’ allele of rs11886868. The high F ‘A’ allele of 
rs4671393 showed a TTF1 binding site, which acts as a transcription termination 
factor for RNA polymerase I. RAF binding site was found near the opposite allele ‘G’ 
(high HbF), which is also involved in transcription repression.   
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Figure 8.3 Transcription factor binding map for SNP rs1427407. A) ‘T’ nucleotide in high HbF and B) ‘G’ 
nucleotide in low HbF genotypes. Transcription factor binding sites are displayed below the 50bp sequence. 
The bracketed values show the log likelihood score of predicted transcription factor binding. The higher the 











Figure 8.4 Transcription factor binding map for SNP rs766432. A) ‘C’ nucleotide in high HbF and B) ‘A’ 
nucleotide in low HbF genotypes. Transcription factor binding sites are displayed below the 50bp 
sequence. The bracketed values show the log likelihood score of predicted transcription factor binding. 












Figure 8.5 Transcription factor binding map for SNP rs11886868. A) ‘C’ nucleotide in high HbF and B) ‘T’ 
nucleotide in low HbF genotypes. Transcription factor binding sites are displayed below the 50bp 
sequence. The bracketed values show the log likelihood score of predicted transcription factor binding. 








           
 
       
     
Figure 8.6 Transcription factor binding map for SNP rs4671393. A) ‘A’ nucleotide in high HbF and B) ‘G’ 
nucleotide in low HbF genotypes. Transcription factor binding sites are displayed below the 50bp 
sequence. The bracketed values show the log likelihood score of predicted transcription factor binding. 






8.2.3 Functional analysis BCL11A intron 2 by reporter assay  
The chosen method to test the function of the QTL SNPs was an enhancer assay based 
on a luciferase reporter system (Promega, UK). Primers were designed to amplify 2 
large sections of the QTL containing the key SNPs and the novel GATA-1 binding sites 
(Figure 8.7). DNA from raised and low HbF genotype/phenotype individuals were used 
and compared in the luciferase assay. A third amplicon was designed from the β-globin 
HS3 LCR region (chr11: 5260110-5264249) which could act as a positive control in the 
enhancer assay. 
 
Figure 8.7 BCL11A gene locus on chromosome 2 showing the position of the putative enhancer regions 
being tested in intron 2, including the GATA-1 sites. Blue horizontal bars represent the gene and the 
track below this shows the key SNPs. Enhancer amplicon 1 (chr2 60570995-60575110) and Enhancer 
amplicon 2 (chr2 60575003-60579344) are indicated at the bottom by black horizontal lines. 
 
The reported vector chosen was a minimal promoter variant of the pGL4 vector series 
from Promega (Figure 8.8). This vector is used for testing the enhancer activity of DNA. 
It carries a minimal mammalian promoter which drives the luciferase gene. 
171 
 
 Figure 8.8. Map of the pGL4.23[luc2/minP] Vector (Promega, UK). For the enhancer 1 (chr2: 60570995-
60575110) and HS3 (chr11;5260110-5264249) contructs, the KpnI and NheI sites were used. For the 
Enhancer 2 construct (chr2: 60575003-60579344), XhoI was used. 
 
DNA was taken from two of the fully sequenced individuals (4041; low HbF-associated 
SNPs and 3180; high HbF-associated SNPs in BCL11A). Enhancer 1 (Enh1) and Enhancer 
2 (Enh2) primer pairs were used to amplify their respective targets (Appendix 1, Table 
11.3). The PCR products were gel purified and cloned into the TOPO-Blunt vector 
(Invitrogen, UK). Plasmids from several clones were prepared and subjected to 
restriction digest to verify that the insert contained insert of the correct genotype 
(Appendix 3, Figure 11.4 & 11.5 for enhancer 1 construct, and Figure 11.6 &11.7 for 
Enhancer 2 construct). 
Following clone identity verification, the enhancers were transferred to the pGL4.23 
vector. Plasmids were digested with KpnI/NheI for the Enh1 construct and with XhoI 
for the Enh 2 construct. This was followed by gel purification of the released fragment, 
and ligation into the pEF vector (using the Roche Rapid Ligation Kit according to the 
manufacturer’s protocol). Plasmid mini-preps were prepared from several colonies, 
and midi-preps before electroporation into K562 cells. 
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Each electroporation was carried out using 3 separate plasmid samples. After 48 hrs in 
culture, cells were harvested and assayed (using the Promego Dual Glo luciferase kit 
according to manufacturer’s instructions). Luminometer reads were taken and each 
sample read 6 times (Figure 8.9). All methods used can be found in Chapter 2. 
The data in Figure 8.9 show that there is some enhancer activity present in the Enh1 
region but no significant difference between the “high” and “low” HbF individuals. The 
Enh2 constructs show a modest increase in enhancer activity, although again, there is 
no significant difference between the two genotypes. The HS3 enhancer shows the 




Figure 8.9 Results of the BCL11A enhancer reporter assays. The first lane is the empty pGL4.23 vector, 
used to assess background signal. Lanes 2 and 3 are results from the Enhancer 1 construct from the 
“high” (3180) and “low” (4041) HbF individuals, respectively. Lanes 4 and 5 are the corresponding 
Enhancer 2 constructs which contain known GATA-1 binding sites. Lane 6 shows the positive control β-
globin HS3 region. 





I re-sequenced the high scoring region of BCL11A intron 2 in individuals with high and 
low HbF phenotypes with corresponding genotypes. Sequence analysis revealed no 
gross or micro deletions or rearrangements in the sequence and no novel SNPs were 
found. The known SNPs were confirmed in these individuals suggesting that these 
SNPs are the causative sequence variants, and therefore the phenotype we see is most 
likely due to the effect of one or more of these polymorphisms.  
A simple transcription factor binding site (TFBS) analysis revealed some TFBS were 
different between the high HbF and low HbF SNPs. Differences in score of TFBS 
indicates likelihood of a true binding site (higher score means it is more likely to be a 
true binding site and vice versa). Some of these factors are involved in repression or 
activation of promoters, histone modification and RNA polymerase II assembly. It is 
possible that the changes in the SNP alleles affect binding of these transcription factors 
which has a downstream effect on HbF production via altered BCL11A transcription. 
Moreover, if a TFBS near a SNP (such as the c-Myb binding site- Figure 8.3) is not 
altered, it is still possible that another factor binding to the c-MYb protein may be 
affected by this SNP. It is, however, noteworthy that this type of TFBS analysis is based 
on a prediction tool and in vitro studies are warranted to validate true differences in 
transcription factor binding. 
To further distinguish how this region functions we studied part of the intron 2 
sequence for enhancer activity. There was slightly higher activity in the enhancer 2 
region which contains the GATA-1 sites; but we found no significant difference in 
enhancer like activity between the high and low F genotypes.  
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Although we did show evidence of general enhancer activity, we do, however, realize 
that the experiment design could be optimised. Amplicon design may not have been 
sufficient to incorporate all the important regions of the enhancer. Individual regions 
of an enhancer element may not show activity in isolation but only function in 
combination with other elements. An example is the β-globin LCR; individually only the 
β-globin LCR HS2 and 3 show enhancer activity on β-globin expression in stable 
reporter assays, however, the presence of HS1 and 4 are required for full induction of 
β-globin expression (Collis et al, 1990). Dividing the region in different constructs, as 
we have done, could disrupt the regulatory function of a potential enhancer. 
The region may also need other elements for the enhancer to be fully functional, 
possibly trans-factors such as transcription factors which were not available in the 
K562 cell environment in which the constructs were transfected. This is possible as 
K562 cells do not naturally express high levels of BCL11A, which may be due to the loss 
of important factors required for BCL11A expression (Andersson et al. 1979). 
Transfection efficiency is another factor which could have led to sub-optimal results. 
For these reasons other cell lines should be tested and even transgenic mouse models 
should be explored. The enhancer construct itself was prepared in one orientation 
which may not have been the correct one for the enhancer to function properly. 
The findings of this experiment therefore do not disprove the hypothesis of an 
enhancer element in intron 2, but a better planned study is required to fully 
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Genetic loci have been identified through family studies and GWAS as QTLs for HbF 
levels (Thein et al. 1987, Garner et al. 1998, Menzel et al. 2007). Two of these QTLs are 
trans-acting and un-related to the β-globin locus. The first was found in an intergenic 
region on chromosome 6q23 (HMIP) between two genes; HBS1L and MYB, which was 
known to be involved in erythropoiesis (Oh et al. 1999). The second and most recently 
identified QTL maps to intron 2 of a little studied gene called BCL11A on chromosome 
2p15, which was previously implicated in B and T cell malignancies (Liu et al. 2003, Liu 
et al. 2006). 
The aim of this research was to characterise these QTL to reveal the mechanism(s) by 
which they themselves are regulated and how they might affect HbF levels. HbF 
expression is stage specifically controlled in embryonic and fetal life. The continuous 
production of HbF into adult life has ameliorating effects in sickle cell disease (SCD) 
and β-thalassaemia, greatly reducing morbidity and mortality. The therapeutic 
targeted re-activation of HbF in the population suffering from these β-
haemoglobinopathies could reduce disease severity and greatly increase quality of life 
and lessen the burden on the public health services.  
The mechanism by which these QTLs influence the developmental control of the globin 
switch (γ-globin to β-globin), is poorly understood, but if comprehended, will provide 
better understanding, not only of globin gene regulation but also give insights in to the 
general mechanisms by which all genes are controlled developmentally, in humans.  
This study has revealed substantial novel data regarding the regulatory nature of these 




9.1 Discussion and further work 
9.1.1  The HMIP QTL is indicative of a regulatory region 
 
We have demonstrated in chapter 4.0 that the HMIP region has characteristics of a 
regulatory element. High levels of AcH3 and RNA Pol II binding reveal that the region is 
transcriptionally active. GATA-1 erythroid transcription factor binds at DNase I 
hypersensitive sites in the highest scoring block within the HMIP region- HMIP2, which 
is indicative of an erythroid-specific regulatory element. 
The MYB gene has a role in erythroid progenitor cell proliferation and differentiation 
(Oh et al. 1999, Jiang et al. 2006) and altered levels can affect the rate of erythroid 
maturation. It is possible that the HMIP intergenic region regulates the MYB gene, 
which alters erythropoiesis (via altered erythroid kinetics) and indirectly affects HbF 
levels. 
To further characterise this region I wanted to investigate any differences between 
individuals with high and low HbF phenotypes and corresponding genotypes. I 
assessed GATA-1 binding in the QTL region in high and low HbF individuals and found 
one GATA-1 signal absent in the high HbF individual.  
This binding site was also in coincidence with DNase I hypersensitive site (HS3). This 
may be a causative variant which may interfere with the regulatory capacity of the 
HMIP region, causing altered MYB expression as seen in high HbF individuals (Jiang et 
al. 2006), and lead to the high HbF phenotype (as a result of more immature higher 
HbF expressing erythroid cells in circulation) (Jiang et al. 2006). 
Assessment of KLF1 binding at the HMIP QTL revealed strong KLF1 binding in the MYB 
promoter and lesser binding in intron 1.  Studies have shown that MYB introns contain 
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regulatory sequences involved in its control (Bender et al. 1987, Dooley et al. 1996, 
Seib et al. 1994). No binding was found in the intergenic HMIP region. Several factors 
have been suggested to regulate MYB expression including GATA-1 (Bartunek et al. 
2003); it is possible KLF1 is also involved in MYB gene regulation.  
Furthermore, taken together with other studies, our data suggests that the 
transcriptional activity in this region is erythroid-specific since it was not seen in other 
non-erythroid cells (Wahlberg et al. 2009).  
The GATA-1 binding data is not quantitative and would need to be validated by qPCR. 
More functional studies of this site are being done to fully understand its potential in 
influencing HbF indirectly via MYB and/or HBS1L. 
Partly on the basis of our findings, others have reported further studies in MYB 
regulation. Stadhouders et al. (2012) have shown, through ChIP-seq experiments to 
identify binding sites of key transcription factors, possible enhancers in HMIP and 
demonstrated that they form an active chromatin hub (ACH) incorporating the MYB 
promoter and intron 1. These findings are in agreement with transcription factor 
binding (KLF1 and BCL11A) that I have shown at intron 1 of MYB through ChIP-chip 
experiments (Figure 5.6).  
Although we have documented and published evidence to support the regulatory 
nature of the HBS1L-MYB intergenic QTL, this needs to be validated and further 
characterised. 
A possible way to assess how HMIP regulates MYB/HBS1L is by studying the physical 
interactions between the two. A useful method to do this is chromatin conformation 
capture (3C), a technique that allows the analysis of chromosome organisation in its 
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native state. Chromosomal regions can fold in order to bring enhancers and 
transcription factors closer to a gene to be transcribed, in this way we could determine 
if the HMIP region physically interacts with the flanking genes. Indeed, our 
collaborators have recently published such an analysis in the mouse locus 
(Stadhouders et al. 2012). 
Targeted deletions of the region and the effect on the HBS1L/MYB genes can help 
determine the regulatory capacity of the region. Yeast artificial chromosomes (YAC) 
have been widely employed for functional analysis of the human β-globin locus in this 
way (Fedosyuk & Peterson, 2007, Navas et al. 2006, Navas et al. 2002, Bungert et al. 
1999). YACs containing the intergenic QTL with deletions of specific sequences in 
transgenic mouse models or stably transfected cell lines would be used to measure the 
effect on the HBS1L/MYB genes. Alteration in the expression of these genes as a result 
of the QTL disruption could verify if the sequence is part of a regulatory element. 
It is also important to further characterise the SNPs in HMIP block 2, which have the 
highest association with HbF levels and are located close to the GATA-1 sites. 
Electrophoretic mobility shift assays (EMSA) and differential allelic expression analysis 
would aid in identifying the causative SNP allele.  
EMSAs are used to study protein–DNA or protein–RNA interactions and can determine 
if one or more proteins tend to bind to a specific DNA or RNA sequence. In our case we 
would be interested in determining any difference in transcription factor binding in the 
presence of the different SNP alleles. 
Differential allelic expression measures the relative expression levels of two alleles of 
one gene. In a heterozygote for a functional cis-acting SNP that affects expression of a 
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gene, the mRNA from each copy of the gene will be expressed differently. An 
expressed SNP can be used as a marker to distinguish the mRNA transcripts of each 
allele. On-going work to elucidate the SNP functions is being undertaken by others in 
our group using such approaches. 
 
9.1.2 BCL11A contains an auto-regulatory element in intron 2 and itself acts 
as a transcription factor at multiple loci. 
 
BCL11A binding was frequently found to coincide with GATA-1 binding at erythroid-
related loci including the α-globin and β-globin loci, thus demonstrating the regulatory 
role of BCL11A on globin expression (Sankaran et al. 2009). BCL11A is known to 
associate with the NuRD chromatin-remodelling complex and other transcription 
factors (Sankaran et al. 2008).  I have provided, for the first time, an extensive multi-
locus analysis of BCL11A, which has helped to demonstrate its role as an erythroid-
related transcription factor. 
As to the regulation of BCL11A itself, I have found very strong GATA-1 binding at 
BCL11A in intron 2, accompanied with high levels of transcriptional activity (ACH3 and 
RNA pol II). Three of the highest scoring SNPs are found near these GATA-1 sites.  
Most research has been focused on the role of the gene in the regulation of γ-globin 
and HbF production (Sankaran et al. 2008 & 2009, Borg et al.2010, Zhou et al. 2010, Xu 
et al. 2012), and not on the regulation of the gene itself, which we believe may be 
controlled in some part by the intron 2 region. We have made efforts to understand 
this region and though our data indicates that the QTL is likely to be a control region of 
the gene, the mechanism by which this sequence exerts its regulatory role on BCL11A 
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expression is still to be determined, although it may regulate the levels of the various 
isoforms produced from this gene. 
Through ChIP-on-chip experiments, I found KLF1 occupies sites on the BCL11A gene. 
Binding sites were identified at the promoter region of the gene and a second site on 
exon 4 which is specific to the larger BCL11A isoforms (XL & L), which we and others 
have found to be predominant in primary human erythroid progenitor cells (Sankaran 
et al. 2008). 
SNPs in the BCL11A QTL are the causative variants in HbF levels.                                  
Re-sequencing the BCL11A intron 2 QTL in extreme trait phenotype/genotypes showed 
no novel sequence variants, insertions or deletions, thereby confirming that the HbF 
phenotypes are due to one or more of the known SNPs. Work should now focus on 
elucidating how these SNPs cause the observed effect on HbF levels.  
We further studied this region in high and low HbF individuals by screening the area in 
two fragments (Figure 8.7) for enhancer activity by luciferase reporter assay. We found 
slightly higher enhancer activity in the second fragment  (Enhancer 2, Figure 8.9) which 
contained the GATA-1 sites, but found no significant difference between the high and 
low HbF individuals. 
I found KLF1 activity on regulatory elements at both globin loci and binding of KLF1 
was often found in parallel with GATA-1 binding. This is not unexpected as KLF1 
participation in complexes with other erythroid transcription factors has been 





Elements on chromosome 7 may affect BCL11A expression.     
 In an attempt to gain better understanding of the BCL11A isoforms, I measured levels 
of the isoforms in myeloid leukaemia. I found higher levels of L and S forms in cases 
with monosomy 7 or (del) 7q compared to all other myeloid leukaemia disease groups 
and the control group studied. Studies have linked sequence variants on chromosome 
7 with haematological parameters (Soranzo et al. 2009) and genes related to 
haematopoetic progenitor cell proliferation and blood cell function are found to be 
dysregulated in M07 cases (Chen et al. 2004).  
It is possible that an element on chromosome 7 may be involved in the regulation of 
the expression of the BCL11A isoforms, but narrowing this down to a region of 7q is 
difficult. There are very few erythroid related genes on chromosome 7, though there 
are more than 70 miRNAs. It is therefore a reasonable possibility that an miRNA 
encoded on chromosome 7q regulates translation of the isoforms. Individual miRNAs 
could be used to determine if there is any isoforms-specific effect on BCL11A. A rapid 
cell-based assay would be relatively simple to set up. 
miRNA target prediction software would be a first step to identify candidate miRNAs 
that may bind BCL11A directly or indirectly. Once these are identified- miRNA 
knockdown studies would prove a suitable method to detect changes in expression 
levels of isoforms and verify the miRNA target. 
HbF data for MO7 and (del)7q cases are very rarely available, but may provide a 
further link to BCL11A regulation. More work is necessary to uncover any associations 




The Intron 2 QTL on BCL11A is indicative of a regulatory region which may act as an 
enhancer of the gene. We made attempts to identify any enhancer-like activity in the 
area but the data produced was not substantial. It is worth using a better system to 
study the region for enhancer activity using a more reliable reporter assay or again, a 
large clone deletion/transgenic study. 
Re-sequencing work in extreme phenotypes and genotypes confirmed that the known 
SNPs in the region, alone or collectively cause the variation in HbF levels in Northern 
Europeans. Which particular SNPs are causing the effect is unknown. One method to 
distinguish the causative SNP(s) is to measure differential transcription factor binding 
sites at important SNPs. We carried out some basic TFBS analysis using online TFBS 
prediction tools, but this is a fairly crude way to assess transcription factors at a given 
sequence. TFBS can only really be verified by in vitro or in vivo studies as is presently 
being carried out at the HMIP QTL. 
Differential transcription factor binding results could be verified by ChIP analysis of 
human primary erythroid precursor cells cultured from individuals with the 
appropriate genotype.  
BCL11A is a promising target for the therapy of SCD and β-thalassaemia as discussed in 
chapter 1.8.4.1, and studies have already provided evidence for this (Xu et al. 2012). 
These studies however are so far limited to mouse models and furthermore, the 
disruption of BCL11A is likely to have effects on other genes and pathways. For this 





9.2 Concluding statement 
 
The studies documented in this thesis strengthen our knowledge and understanding of 
the HMIP and BCL11A QTLs that influence HbF levels. Further studies are underway by 
our group and others to elucidate the mechanisms of function of these QTLs, which 
will hopefully lead to better understanding of the control of HbF production; 
something that should also prove useful in the therapeutic activation of HbF and 
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Appendix 1- Primer sequences 
 

















Forward primer sequence and exon  
targeted 
Reverse primer sequence and exon 
targeted 
Probe sequence and exon targeted 
α-globin 
TCTGGTCCCCACAGACTCAGA                        
(exon 1) 
GAAGTGCGGGAAGTAGGTCTTG           
(exon 2) 
CCTGGAGAGGATGTTC                             
(exon 1 and 2) 
β-globin 
CTGTGACAAGCTGCACGTGG                         
(exon 2) 
GCCAGCACACAGACCAGCA                   
(exon 3) 
CCTGAGAACTTCAGGCTCCTGGCCAAC  
(exon 2 and 3) 
γ-globin 
CGTCACTGTGACAAGCTGCAT                       
(exon 2) 
CGAAATGGATTGCCAAAACG                 
(exon 3) 
CCAGCACATTTCCCAGGAGCTTGAAGT  
(exon 2 and 3) 
MYB 
ATGATGAAGACCATGAGAAGGAAA             
(exon 7) 
AACAGGTGCACTGTCTCCATGA             
(exon 9) 
TGCTACCAACACAGAACCACACATGCA  
(exon 8 and 9) 
HBS1L 
ACAAGAATGAGGCAACAGTATCTACAG      
(exon 4) 
TCAGATTCACTTCGCGATGTCT              
(exon 5) 
CAAAAGGAAAACCAGTAGATTCC                      
(exon 5) 
GATA1 
CAATGCCTGCGGCCTCTA                              
(exon 5) 
CATCCTTCCGCATGGTCAGT                   
(exon 6) 
CTACAAGCTACACCAGGTGA                   
(exon 5 and 6) 
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Primer target Forward primer sequence Reverse primer sequence 
α-HS40                                                                          
Positive control for GATA1 binding (ChIP) 
CGACCCTCTGGAACCTATCAG TTGGCCTCCAGAAGCACTG 
NEFM                                                                          
Housekeeping gene, negative control and normaliser 
AGCTGGACAAGAAGGTGCAG CCGTCGAGATGTCTGTCTTC 
GAPDH                                                                 
Housekeeping gene, negative control and normaliser 
ACTAGCGGTTTTACGGGCG TCGAACAGGAGGAGCAGAGAGCGA 
HBB promoter   (β-globin)                                          
Positive control for KLF1 binding (ChIP) 
CAATAGATGGCTCTGCCCTGAC CAGGTACGGCTGTCATCACTTA 
β-HS3                                                                              
Positive control for BCL11A binding (ChIP) 
CAGATGGATGGGGCAATGAAG GGGGGTATAGGGGAGCAG 
KLF1 CCCAGTCACTAGGAGAGTCCAA GCTACACCAAGAGCTCCCACCT 
BCL11A Ready-made TaqMan primer mix- Hs00256254.m1 (Invitrogen, UK)  
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Table 11.4 BCL11A intron 2 sequencing primers 
 
Primer target Forward primer sequence 
 
Reverse primer sequence 
Amplicon 1 TTCCCTATCCACAGACCACAGCCC ACAGCCATAACAGGGTTTCCAGTG 
Amplicon 2 ACCGTCTCTTTGGTGCAGTGGGAA AGCCGTCTTTCAGGGTAGCACCAA 
Amplicon 3 TGCGCTTCTCAGACCCAAATGCTC TCCATGGGGAAATGGGTCCTGCTT 







Enhancer amplicon 1 TCATCGGTACCAACTCCTTAAGCCATCATTCCA TCATCGCTAGCTTTCCACTCTTCTCTCCCCATA 
Enhancer amplicon 2 TCATCCTCGAGCCCTCTGTAAACAAGGAGGTTG TCATCCTCGAGCTGCCTGCTTCCTTCTCTTTAC 








Table 11.6 qPCR primers to validate KLF1 ChIP-chip data 
Isoform Forward primer sequence and exon  
targeted 
Reverse primer sequence and exon 
targeted 
XL AGCTCAAAAGAGGGCAGACGCA  
(exon 4) 
CTT CTC CTG TGG ACA GTG AGA TTG  
(exon 4) 
L AGCTCAAAAGAGGGCAGACGCA  
(exon 4) 
AGA ACT TAA GGG CTC TCG AGC TTC  
(exon 5) 
S CGT TCT GCA CAT GGA GCT CTA ATC  
(exon 3) 




CGT TCT GCA CAT GGA GCT CTA ATC 
(exon 3) 






Forward primer sequence 
 
Reverse primer sequence 
 












































    
Primer ID and target isoform Primer sequence 
CF-Bam: (common forward primer for all forms) ttattggatccaccatgtctcgccgcaagcaaggcaaac 
S-R-NotI: (reverse primer for S form) ttattgcggccgcatcaaattttctcagaacttaagggc 
L-R-NotI: (reverse primer for L form) ttattgcggccgcatcagaacttaagggctctcgagctt 




Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 
L 773 aa 
L-R-Not 




Figure 11.1 Design and RT-PCR primer position for the BCL11A over-expression constructs 






Figure 11.2 Schematics of the pEF6 constructs with BCL11A inserts are shown for each of 
the isoforms. The dark regions show the BCL11A cDNAs, flanked by the BamHI and NotI 
cloning sites. The clear regions are pEF6 vector backbone. As part of the test digests to check 
for vector integrity, vector-specific enzymes were also used to assess proper insert 













   
 
Figure 11.3 Restriction digests of 4 plasmid preps from each of the pEF6-cloned BCL11A 
isoforms. The BamHI/NotI digests release the full-length cDNA (XL 2519 bp; L 2333 bp; S 743 
bp), leaving the larger pEF backbone (5.8 kb). The AatII/BsrGi digests check for insert 
orientation: (expected bands if correct: XL: 4243, 2126, 1123 bp; L: 4852, 2126, 1123 bp; S: 
4391, 2126 bp). Having no insert, XL clone number 1 is the only one to be incorrect. 
PhiX/HaeIII DNA ladders (P) are on the outside lanes and Lambda/HindIII (L) are on lanes 6 















Figure 11.4 Verification of the Enhancer 1 construct. The “high” HbF (A) and the “low” HbF 
(B) individual can be distinguished by the presence or absence of an AflII restriction site 
within the SNP rs10172646 (here at position 3,606 of the cloned PCR fragment, which is 
shown by the black bar between the cloning sites KpnI/NheI). The cutter denotes the “G” 
genotype of the “high” HbF individual 3180 (upper panel-A) and the non-cutter denotes the 




 Figure 11.5 Enhancer 1 genotype verification at SNP rs10172646. A 2089 bp AflII fragment 
(indicated by a black arrow) is cleaved by AflII if there is a G nucleotide (the “high” genotype) 
into a 1561 and 529 bp fragments (indicated by white arrows). The “low” genotype, with an 
A nucleotide, does not cut. Samples 3180 and 4041 were used in subsequent experiments. 
206 
 
 Figure 11.6. Verification of the Enhancer 2 construct, the “high” HbF (A) and the “low” 
HbF (B) individual can be distinguished by the presence or absence of an AvaII restriction site 
within the SNP rs7606173 (here at position 4,297 of the cloned PCR fragment, which is 
shown by the black bar between the XhoI cloning site). The cutter denotes the “G” genotype 
of the “high” HbF individual 3180 (upper panel-A) and the non-cutter denotes the “C” 
genotype of the “low” HbF individual 4041 (lower panel-B). 
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Figure 11.7 Enhancer 2 genotype verification at SNP rs7606173. A 395 bp AvaII fragment 
(indicated by a black arrow) is cleaved by AvaII if there is a G nucleotide (the “high” 
genotype) into a 286 and 109 bp fragments (indicated by white arrows). The “low” 















Appendix 4- Patient karyotypes for qPCR studies in Chapter 7 
Table 11.8 AML with Monosomy 7 (-7) or del (7q) (n=30) 
Patient DOB Sample date 
Date  Sample  RNA 
Karyotype 
received type condition 
FP 21-Dec-78 07/06/2007 07/06/2007 Marrow Good 
45,XX,-7[6]/ 
46,XX[4] 
KGC 21-Jan-91 16/08/2007 16/08/2007 Marrow High 
45,XX,-7[12]/ 
46,XX[1] 
RP 06-Aug-35 28/08/2007 29/08/2007 Marrow Good 
45,XY,-7[10]/ 
46,XY[2] 






CH 03-Sep-38 03/11/2008 03/11/2008 Blood High 
45,XX,t(3;6)(q26;q25),-7[10] Metaphase FISH: EVI1 gene  
rearrangement positive[5]    
BR 08-Jan-52 29/01/2009 29/01/2009 Marrow V.High 
46,XY,del(7)(q3q3)[12]/ 
46,XY[1] 
NJ 26-Feb-42 25/11/2009 16/11/2009 Marrow V.High 
45,XY,del(6)(q1q2),-7[9]/ 
46,XY[1] No evidence of a MLL gene rearrangement [106] 





LW 10-Feb-28 04/12/2007 04/12/2007 Marrow Good 
45,XY,-7[9]/ 
46,XY[1] 
JVR 13-May-35 18/08/2008 18/08/2008 Marrow Good 47,XX,del(7)(q22q3),+8[10] 
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SLC 08-Apr-94 28/11/2008 28/11/2008 Marrow V.High 
46,XX,del(7)(q2q3),t(16;16)(p13;q22)[15] CBFB/MYH11 
 gene rearrangement [5] Metaphase FISH analysis 
RG 08-Apr-77 29/09/2009 29/09/2009 Marrow V.High 
46,XX,del(7)(q2q3),t(16;16)(p13;q22)[15] CBFB/MYH11  
gene rearrangement [5] Metaphase FISH analysis 
PW 08-Jul-38 25/01/2010 26/01/2010 Marrow High 46,XY,del(7)(q22q32),inv(16)(p13q22)[9]/ 46,XY[1] 
JAL 29-Nov-00 28/05/2010 29/05/2010 Marrow V.High 
48,XY,del(7)(q31q36),der(16)del(16)(p13p13)inv(16)(p13q22) 
del(16)(q22q22),+22,+r[10] CBFB/MYH11 positive Metaphase 
 FISH analysis 
DD 06-Oct-41 09/09/2010 10/09/2010 Marrow High 
46,XY,del(7)(q2)[5]/ 
46,XY[64] Loss of one copy of D7S522 [4/99] Interphase  
FISH analysis 




DD 27-Jun-24 22/10/2007 22/10/2007 Marrow Good 45,XX,-7,+14,i(14)(q10)[10] 
CM 02-Apr-42 20/03/2008 20/03/2008 Marrow Good 
46,XY,del(7)(q2q3)[9]/ 
46,XY[1] 




Interphase FISH: PML/RARA gene rearrangement positive 
[21/105]    
13q14 deleted x1 [19/110]           
HH 28-Jul-32 23/06/2009 24/06/2009 Marrow High 46,XY,-3,add(3)(q1),-7,dic(13;18)(p1;p1),+mar1,+mar2,+r[8] 





RG 13-Apr-46 05/09/2008 05/09/2008 Marrow Good 45,XY,-7[13]/46,XY[2] 




SRC 29-Oct-33 13/02/2008 13/02/2008 Marrow Good 45,XX,-7[13]/46,XX[2] 
KJ 15-Feb-92 06/11/2008 07/11/2008 Marrow Good 5,XX,-7[8]/46,XX[2] 
MA 28-Jan-46 23/12/2008 23/12/2008 Marrow V.High 
45,XY,t(3;3)(q21;q26),-7[9]/46,XY[1] EVI1 rearrangement 
positive [5/5],  
Metaphase FISH 
GF 12-Aug-45 03/06/2009 04/06/2009 Blood High 





EAJ 11-Mar-05 04/09/2009 05/09/2009 Marrow High 45,XY,-7[20] 
KM 19-Mar-40 19/02/2010 19/02/2010 Marrow V.High 45,XY,-7[10] 





Table 11.9 JMML samples (n=6) 











MI 10-Feb-05 19/07/2007 19/07/2007 Blood Good 46,XY[20] 
NJEC 11-Mar-06 22/11/2007 23/11/2007 Marrow Good 46,XX[20] 
RAK 31-Mar-09 30/07/2010 31/07/2010 Marrow Good 46,XX[20] 
SL 28-Apr-03 15/09/2005 15/09/2005 Marrow Very high 46,XX[20] 
IH 13-May-03 03/01/2006 03/01/2006 Marrow High 46,XY,-6,+r[3]/ 46,XY[37] 




Table 11.10 CMML samples (n=10) 










MP 11-Mar-36 06/04/2009 07/04/2009 Marrow V.High 46,XX[20] 
TN 02-Jun-45 22/04/2010 23/04/2010 Marrow V.High 46,XY[20] 
KS 08-Oct-40 16/10/2009 16/10/2009 Blood High 
PDGFRA gene rearrangement negative [110]             
PDGFRB gene rearrangement negative [96] 
Interphase FISH analysis          
LA 22-May-27 10/08/2009 12/08/2009 Marrow High 46,XY[20] 
BS 10-Jun-37 08/09/2009 08/09/2009 Marrow High 46,XY[20] 
VN 04-Jun-23 01/02/2010 01/02/2010 Marrow V.High 46,XX[20] 
NJB 20-Aug-43 02/02/2010 03/02/2010 Blood High 46,XY[20] 
BK 05-Sep-30 09/04/2010 10/04/2010 Blood Good 46,XX[20] 
IM 18-Jun-31 05/05/2010 06/05/2010 Blood Good 46,XX[20] 








 Table 11.11 AML with normal karyotype 










DD 24-Dec-55 01/06/09 01/06/09 Marrow High 46,XY[20] 
HA 12-Jul-53 28/08/09 28/08/09 Marrow V.high 46,XX[20] 
FD 11-Jun-39 15/06/09 16/06/09 Marrow V.High 46,XX[20] 
LG 23-Dec-64 18/06/09 18/06/09 Marrow High 46,XX[20] 
HB 15-Apr-45 06/07/09 07/07/09 Marrow Good 46,XX[20] 
RG 02-Apr-36 08/07/09 09/07/09 Marrow V.High 46,XX[20] 
FN 09-Aug-45 13/07/09 14/07/09 Marrow V.High 46,XY[20] 
GH 13-Oct-44 14/07/09 15/07/09 Blood High 46,XY[20] 
LG 25-Nov-34 27/07/09 28/07/09 Marrow V.High 46,XY[20] 
MD 26-Sep-49 17/08/09 17/08/09 Marrow Good 46,XY[20] 
 
 
Table 11.12 Control group 









CB 16-Sep-51 13/03/08 13/03/08 Marrow good 
CBH 06-Oct-43 27/06/08 27/06/08 Marrow high 
ES 06-Sep-40 12/08/08 13/08/08 Marrow good 
AW 26-Mar-01 04/06/09 04/06/09 Marrow v.high 
BW 10-Feb-36 16/09/09 16/09/09 Marrow high 
CB 07-Sep-41 25/09/09 25/09/09 Marrow high 
EM 09/01/1997 09/05/08 09/05/08 Marrow high 
WC 27/11/1934 17/03/08 17/03/08 Marrow high 
EM 27-Mar-44 23/12/08 23/12/08 Marrow good 








Appendix 5- List of abbreviations 
 
ACH   Active chromatin hub 
AcH3   Acetylated histone H3 
AcH4   Acetylated histone H4 
αHS40   α-globin locus DNase I hypersensitive site 40 
AML   Acute myeloid leukaemia 
βHS3   β-globin LCR DNase I hypersensitive site 3 
BFU-e   Burst forming unit erythroid 
Bp   Base pairs 
CFU-e    Colony forming unit erythroid 
ChIP-chip  Chromatin immunoprecipitation on microarray 
CMML   Chronic myelomonocytic leukaemia 
Cy3   Cyanine 3 
Cy5   Cyanine 5 
Enh   Enhancer 
EPO   Erythropoietin 
ERC   Erythropoietin responsive cells 
F   Fetal haemoglobin 
FACS   Fluorescence activated cell sorting  
FC   F-cells 
FCS   Foetal calf serum 
FOG-1   Friend of GATA-1 
GM-CSF  Granulocyte-macrophage colony stimulating factor 
GPA   Glycophorin A 
HbA   Adult haemoglobin (α2β2) 




HbA2   Haemoglobin minor (α2δ2) 
HbAS   Sickle trait, heterozygous for HbS 
HBB   β-globin 
HBBP1   βψ-pseudogene 
HBD   δ-globin 
HBE   ε-globin 
HbF   Foetal haemoglobin (α2γ2) 
HBG   γ-globin 
HBM   ψα2-pseudogene 
HBQ1   θ-globin 
HbS   Sickle haemoglobin, α2β
s
2  
HBZ   ζ-globin 
HMIP   HBS1L-MYB intergenic polymorphism 
Ho   Human orthologous 
HPC   Haematopoietic progenitor cell 
HPFH   Hereditary persistence of foetal haemoglobin 
HS   Hypersensitive site (to Dnase I) 
HSC   Haematopoietic stem cell 
IL-3   Interleukin 3 
JMML   Juvenile myelomonocytic leukeamia 
Kb   Kilo base pairs 
KLF   Krüpple like factor-1 
LCR   Locus control region 
LD   Likage disequilibrium 
LINE   Long interspersed nuclear element 
LME   L-leucine methyl ester 
LTR   Long terminal repeat 




MDS   Myelodysplastic syndrome 
MO7   Monosomy 7 
MYB   Myeloblastosis oncogene 
NEFM   Neurofilament medium gene 
PB   Peripheral blood 
PBS   Phosphate buffered saline 
PBST   Phosphate buffered saline-Tween 
PCR   Polymerase chain reaction 
Q-PCR   Quantitative PCR 
QTL   Quantitative trait locus 
RNAP II  RNA polymerase II 
RT-PCR  Reverse transcription PCR 
SCD   Sickle cell disease 
SCF   Stem cell factor 
SNP   Single nucleotide polymorphism 
TFBS   Transcription factor binding site 
TF   Transcription factor 
TSS   Transcriptional start site 
UTR   Untranslated region 
YAC   Yeast artificial chromosome 
(del) 7q  Deletions within the q arm of chromosome 7 
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